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Abstract: In diagnostic microbiology, culture media are widely used for detection of pathogenic 
bacteria. Such media employ various ingredients to optimize detection of specific pathogens such 
as chromogenic enzyme substrates and selective inhibitors to reduce the presence of commensal 
bacteria. Despite this, it is rarely possible to inhibit the growth of all commensal bacteria, and thus 
pathogens can be overgrown and remain undetected. One approach to attempt to remedy this is the 
use of “suicide substrates” that can target specific bacterial enzymes and selectively inhibit 
unwanted bacterial species. With the purpose of identifying novel selective inhibitors, six novel 
phosphonopeptide derivatives based on D/L-fosfalin and β-chloro-L-alanine were synthesized and 
tested on 19 different strains of clinically relevant bacteria. Several compounds show potential as 
useful selective agents that could be exploited in the recovery of several bacterial pathogens 
including Salmonella, Pseudomonas aeruginosa, and Listeria. 
Keywords: bacterial detection; suicide substrates; fosfalin; β-chloroalanine.  
 
1. Introduction 
Antimicrobial resistance (AMR) is rapidly becoming a global crisis. According to the Centers for 
Disease Control and Prevention (CDC), around 2.8 million people are infected with antibiotic-
resistant bacteria and approximately 35,000 deaths occur each year in the USA due to these infections 
[1,2]. Moreover, the O’Neill report estimates that there will be 10 million deaths globally each year 
due to antibiotic-resistant bacteria by 2050 (O’Neill’s AMR report, 2016). This impending crisis has 
reinforced the need for new, rapid, economical and user-friendly bacterial detection and 
identification methods. These tools will prove crucial in the years ahead in order to facilitate antibiotic 
stewardship, particularly in the selection of the most effective antibiotic to control specific pathogenic 
bacteria. 
Chromogenic and fluorogenic enzymatic substrates are established diagnostic tools used in 
clinical microbiology for pathogen identification [3,4]. Used alone however, these diagnostic tools 
face two major problems: i) The presence of abundant commensal bacteria within clinical samples 
can camouflage the detection of low amounts of pathogenic bacteria, and ii) production of similar 
enzymes by different strains or species that act upon the same enzymatic substrate can lead to false 
results. Due to this, incorporation of specific and selective growth inhibitors such as L-alanyl-L-
fosfalin 1 (Figure 1) into the growth medium is of clinical interest [5], as such substances may inhibit 
Molecules 2020, 25, 1557 2 of 25 
 
the growth of interfering microbes while allowing a pathogen of interest to grow unhindered. Once 
inside bacterial cells, cleavage of the peptide bond of L-alanyl-L-fosfalin occurs, releasing the active 
substance L-fosfalin 2-L (Figure 1). This in turn binds to alanine racemase (AlaR), a bacterial enzyme 
that catalyzes the isomerization of L-alanine to D-alanine 3-D (Figure 1) utilizing a pyridoxal 5′-
phosphate cofactor [6]. As D-alanine is a crucial building block for bacterial cell wall formation [7], 
bacterial growth is hindered if the enzyme is inhibited. The expression of L-alanine aminopeptidase 
for peptide bond cleavage is found more readily in Gram-negative than Gram-positive bacteria [8]. 
In addition, some bacteria either do not take in the pseudo-dipeptide or it is removed rapidly by 
efflux pumps [9]. The combination of these factors provides a basis for selective inhibition of bacterial 
cell growth in culture. 
 
Figure 1. Structures of L-alanyl-L-fosfalin 1, fosfalin 2, alanine 3, β-chloroalanine 4. 
Although fosfalin is a known inhibitor, its use as a single pseudo-amino acid residue is limited 
due to the multiply ionised forms of fosfalin found at physiologically relevant pH values. This factor 
reduces its ability to penetrate the cell membrane by passive diffusion. However, dipeptide 
inhibitors, such as L-alanyl-L-fosfalin, can bypass the cell membrane by hijacking di/tripeptide 
transporter systems found within the cell membrane [10]. 
Low minimum inhibitory concentrations (MICs) were observed upon replacing the L-alanine 
with different hydrophobic L-amino acids, especially L-methionine and L-norvaline at the N-terminus 
of phosphonodipeptide derivatives containing fosfalin [11,12]. Moreover, selective inhibition against 
Escherichia coli, Klebsiella species and Enterococcus faecalis has previously been found by replacing the 
L-alanine at the N-terminus of phosphonotripeptides with sarcosine [13]. 
Elsewhere, it has been shown that the alanine analogue β-chloroalanine 4 (Figure 1) is known to 
display irreversible inhibition towards alanine racemase [14]. In studies performed and reviewed by 
Atherton et al. [11–13] and Cheung et al. [15,16] it has been shown that β-chloroalanine exhibits good 
antibacterial activity alone as well as upon coupling with other peptides or amino acids. 
Although many studies have been performed in the past based on fosfalin or β-chloroalanine 
peptide derivatives, to the best of our knowledge, no studies on the antimicrobial effects of molecules 
incorporating both of these inhibitors into a single peptide-like derivative have been reported. 
Herein, a range of phosphonotripeptides based either on a single inhibitor, D/L-fosfalin, or containing 
dual inhibitors, D/L-fosfalin and β-chloro-L-alanine, coupled to a variety of different N-terminal units 
in the form of sarcosine, L-norvaline or L-methionine were synthesized. The antibacterial activity of 
the resulting phosphonotripeptides was evaluated against 19 different strains of clinically relevant 
bacteria. Although L-fosfalin is most commonly studied version of this particular inhibitory unit, it is 
costly to produce. This factor may limit its use in the developing nations which lie on the front-line 
of the battle against emergent drug resistant bacteria. With this in mind, the racemic version of this 
unit, D/L-fosfalin was utilized in our studies, due to its relatively facile, and thus economical, 
production.  
2. Results and Discussion 
2.1. Synthesis of Inhibitors: D/L-Fosfalin and β-Chloro-L-Alanine Derivatives 
Several synthetic methodologies producing fosfalin are known, including production of its 
enantiomerically pure forms [17–20]. Here however, synthesis of racemic fosfalin, i.e., D/L-fosfalin, 
was utilized due to its more economical synthesis. In our previous unpublished investigations, we 
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have seen that whenever the enantiomerically pure form of fosfalin has been utilized within a peptide 
sequence the activity is always twice that of the analogous compound containing the racemic version 
of fosfalin. This is in keeping with the notion that one isomer of fosfalin is active and the other is 
completely inactive. As the intended use in the present work is to produce economically viable 
diagnostic tools rather than potent antimicrobial agents, we elected to utilize the racemic version of 
this warhead within this study. To that end, a good yield of D/L-fosfalin was obtained in one-pot, 
using N-phenylthiourea 5, acetaldehyde 6 and triphenyl phosphite 7 under acidic conditions (Scheme 
1). From there, two different protecting groups, N-trifluoroacetyl and an O-phosphonodiethyl ester 
group were introduced orthogonally at the N-terminus and O-terminus of racemic fosfalin 
respectively. Upon removal of N-trifluoroacetyl protecting group 8 by sodium borohydride, D/L-
fosfalin diethyl ester 9 was isolated. 
 
Scheme 1. Synthesis of D/L-fosfalin diethyl ester. Reagents and conditions: i) AcOH, reflux, 1 h; ii) 
AcOH/HCl (1:10), reflux 24 h; iii) EtOH; iv) CF3COOH/(CF3CO)2O (1:5), reflux 1 h; v) CH(OC2H5)3, 
reflux 2 h; (vi) NaBH4, reflux 4 h. 
Producing the enantiomerically pure β-chloro-L-alanine derivatives, Boc-β-chloro-L-alanine 13 
and β-chloro-L-alanine benzyl ester hydrochloride salt 14 was a more economical proposition than 
the fosfalin unit. Thus, these materials were prepared in their enantiomerically pure forms from an 
inexpensive and readily available chiral precursor, Boc-L-serine 10. To produce the required 
molecules, the precursor was subjected to base-catalyzed esterification, followed by chlorination and 
then chemoselective deprotection (Scheme 2). The corresponding intermediates, Boc-L-Ser-OBzl 11 
and Boc-β-Cl-L-Ala-OBzl 12 were isolated in good yield. 
 
Scheme 2. Synthesis of β-chloro-L-alanine derivatives, Boc-β-chloro-L-alanine 13 and β-chloro-L-
alanine benzyl ester hydrochloride salt 14. Reagents and conditions: i) DBU, benzyl bromide, dry 
benzene, r.t., 24 h; ii) trichloroacetonitrile, PPh3, dry DCM, r.t., 24 h; iii) MeOH, 10% Pd/C, 3.5 bar H2, 
r.t., 24 h; iv) 2M HCl in diethyl ether, r.t., 48 h. Caution: Benzene is a known carcinogen. 
2.2. Synthesis of Phosphonotripeptide Derivatives 
D/L-fosfalin diethyl ester 9 was coupled to three dipeptides producing a series of tripeptides with 
a central alanine residue and a variable N-terminal residue (Scheme 3). For this position we chose the 
amino acids that Atherton et al. [11–13] had indicated produced interesting effects in terms of 
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bacterial cell permeation and MIC enhancement, namely sarcosine (Sar), methionine (Met), and 
norvaline (Nva). In a second series, L-alanine was replaced by β-chloro-L-alanine at the central 
position thus producing a series that contained two inhibitors within each tripeptide strand. In total, 
this resulted in six different phosphonotripeptide derivatives, L-Nva-L-Ala-D/L-Fos 21a, Sar-L-Ala-
D/L-Fos 21b, L-Met-L-Ala-D/L-Fos 21c, L-Nva-β-chloro-L-Ala-D/L-Fos 25a, Sar-β-chloro-L-Ala-D/L-Fos 
25b, L-Met-β-chloro-L-Ala-D/L-Fos 25c. The ratio of diastereoisomers and enantiomers can be found 
within the Supplementary Materials. 
A different coupling strategy was utilized where the reactive amino acid methionine, 15c, was 
employed (Scheme 3, Pathway B). This amino acid displays a sensitive thioether side chain, which is 
prone to oxidation and cyclisation reactions [21]. Therefore, in order minimize these unwanted side 
reactions, methionine was introduced at the last stage of the synthesis of tripeptides (20d and 20e). 
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Scheme 3. Synthesis of phosphonotripeptide derivatives. Reagents and conditions: i) L-Ala-OBzl, 
DIPEA, IBCF, NMM, THF/DCM, −5 °C to r.t., 16–18 h; ii) H2, Pd/C, MeOH, 24 h; iii) 9, IBCF, NMM, 
THF, −5 °C to r.t., 16–18 h; iv) 2 M HCl in diethyl ether, r.t., 48 h; v) 15c, IBCF, NMM, DIPEA, 
THF/DCM, −5 °C to r.t., 16–18 h; vi) HBr, AcOH, 16–18 h then propylene oxide; vii) 14, IBCF, NMM, 
THF/DCM, −5 °C to r.t., 16–18 h; viii) 15c, IBCF, NMM, THF/DCM, −5 °C to r.t., 16–18 h. 
2.3. Microbiological Evaluation 
The inhibitory action of these compounds requires efficient uptake of these molecules across the 
bacterial cell membrane, hydrolysis of specific peptide bonds by aminopeptidases to release the 
inhibitor(s), and binding of inhibitor(s) to AlaR. As different amino acids are utilized at the N-
terminus of the tripeptide derivatives, differences in uptake may result, and different intracellular 
aminopeptidases may be required for the liberation of D/L-fosfalin and β-chloro-L-alanine (where 
incorporated), in order to act on AlaR. The rationale for varying the N-terminal amino acid was that 
as different species and strains of bacteria produce the transporters and enzymes involved with these 
processes to differing extents, differences in antibacterial activity were anticipated. The antimicrobial 
activity of phosphonotripeptide derivatives was evaluated as their minimum inhibitory 
concentration (MIC), Table 1. 
Table 1. Minimum inhibitory concentration of diastereoisomeric L-Nva-L-Ala-D/L-fosfalin 21a, Sar-L-
Ala-D/L-fosfalin 21b, L-Met-L-Ala-L-fosfalin 21c, L-Nva-β-chloro-L-Ala-D/L-fosfalin 25a, Sar-β-chloro-
L-Ala-D/L-fosfalin 25b and L-Met-β-chloro-L-Ala-L-fosfalin 25c against pathogenic bacteria. 
  MIC (mg/L) after 22 h 
  Single Inhibitor Dual Inhibitors 
Species  21a 21b 21c 25a 25b 25c 
Gram negative   
Acinetobacter baumannii ATCC 19606 >8 >8 >8 >8 >8 >8 
Burkholderia cepacia ATCC 25416 >8 >8 >8 >8 >8 >8 
Enterobacter cloacae NCTC 11936 >8 >8 >8 4 >8 4 
Escherichia coli NCTC 10418 2 >8 1 0.5 4 0.5 
Escherichia coli NCTC 12241 2 8 2 0.5 4 0.5 
Klebsiella pneumoniae NCTC 9528 0.5 2 0.25 0.25 2 0.5 
Providencia rettgeri NCTC 7475 >8 >8 >8 >8 >8 >8 
Pseudomonas aeruginosa NCTC 10662 >8 >8 >8 >8 >8 >8 
Salmonella typhimurium NCTC 74 >8 >8 >8 >8 >8 >8 
Salmonella enteritidis NCTC 6676 >8 >8 >8 >8 >8 >8 
Serratia marcescens NCTC 10211 0.25 1 0.25 0.25 2 0.25 
Yersinia enterocolitica NCTC 11176 0.25 0.25 0.25 0.25 0.5 0.25 
Gram positive        
Enterococcus faecalis NCTC 775 0.063 4 0.063 0.063 4 0.032 
Enterococcus faecium NCTC 7171 2 >8 2 1 >8 1 
Listeria monocytogenes NCTC 11994 >8 >8 >8 >8 >8 >8 
Staphylococcus epidermidis NCTC 11047 1 >8 2 2 >8 1 
Staphylococcus aureus NCTC 6571 2 >8 0.5 4 >8 2 
Staphylococcus aureus 
(MRSA) 
NCTC 11939 >8 >8 4 >8 >8 >8 
Streptococcus pyogenes NCTC 8306 NT >8 >8 >8 NT NT 
NT: Not tested because no growth was observed on the positive control in several replicates. Note: 
Negative and positive controls, two plates: One containing suicide substrates only and one containing 
bacteria only were performed. The susceptibility testing of NCTC and ATCC bacteria was established 
by standardized methods [22]. 
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Broadly speaking, all six phosphonopeptide derivatives produced similar inhibitory profiles to 
one another against most bacterial species and strains. However, the extent of activity for the 
collection of inhibitors varied markedly depending on the bacterium in question in a manner that 
does not appear to be specifically tied to the Gram classification of the organism. For instance, 
consistently high activity is seen for all inhibitors for two of the Gram-negative species S. marcescens 
and Y. enterocolitica, with all inhibitors displaying MIC values of 2 mg/L or less. In contrast, no activity 
against six of the remaining Gram-negative organisms tested was observed at the highest inhibitor 
concentration tested, which was 8 mg/L. Turning attention to the Gram-positive organisms low or no 
activity was displayed at the maximum concentrations tested for L. monocytogenes, while very high 
activity (0.063 mg/L or less) was seen against E. faecalis for all inhibitors tested except for 21b and 25b, 
which still retained activity, albeit at the 4 mg/L level. 
In general, compounds 21b and 25b appear to be the least effective in terms of overall inhibitory 
profile. In both instances, the N-terminal amino acid is sarcosine, thus the presence of this amino acid 
in this position of these tripeptide derivatives appears to be detrimental to activity. However, the 
current data set does not definitively explain whether these poor activity profiles derive from poor 
uptake, or from slow liberation of the active units once inside the bacterial cell. In many instances 
these two poorest performing inhibitors have identical MIC values, and when differences do exist 
they are displayed only to the nearest increment that our tests allow. For example, for S. marcecsens 
the substance with a simple alanine 21b produces the greater inhibition (1 mg/L) over its β-chloro 
analogue 25b (2 mg/L). In contrast, for E. coli NCTC 12,241 the reverse behavior is seen with the β-
chloro substance 25b exhibiting MIC = 4 mg/L, whereas in this case the simple alanine containing 
tripeptide 21b produces a weaker MIC of 8 mg/L. Essentially, this indicates that these two poorly 
performing inhibitors display very similar levels of activity over a wide range of organisms. 
With regards to the remaining four inhibitors, there is a subtle yet clear difference in activity for 
the central β-Cl-Ala series vs. the series of compounds with a standard alanine residue at the central 
position. Specifically, 25a and 25c are the most consistently active pair of inhibitors, and contain β-
Cl-Ala at the center position of each tripeptide. Thus, this indicates that the presence of the β-chloro 
unit in the center of the tripeptide is indeed beneficial to overall activity. While not definitive, this 
would indicate that the β-chloro alanine unit is liberated, and becomes active against the bacteria, 
acting in a synergistic manner with the fosfalin unit, which is common to all six inhibitors. 
L-Alanine aminopeptidase is thought to be found more readily in Gram-negative bacteria [8]. 
However, in our data some inhibitory effects extended to certain Gram positive bacteria, namely E. 
faecalis, E. faecium, S. epidermidis, S. aureus, and methicillin resistant S. aureus (MRSA). This suggests 
the likely presence of L-alanine aminopeptidase in these selected Gram-positive bacteria. This finding 
was consistent with results recently reported by Cellier et al. [23], who demonstrated a chromogenic 
response upon hydrolysis of L-alanyl aminopeptidase substrates by E. faecalis and E. faecium. The 
presence of this enzymatic activity in Staphylococcus spp., Streptococcus spp. and E. faecalis has also 
been reported by Hoosain and Lastovica [24]. 
As intimated earlier, the eventual purpose of these compounds was to be incorporated into 
selective culture media for the clinical diagnosis of bacterial infections. Thus, we seek to identify 
substrates that have a wide range of inhibitory activities but leave specific pathogens of interest free 
to grow. Looking at our current data set, this suggests a potential application for two of our β-chloro-
L-alanyl phosphonotripeptides (25a and 25c) in the selective inhibition of specific Gram-negative 
bacteria. Specifically, E. cloacae, E. coli, K. pneumoniae, and S. marcescens are commonly found in cystic 
fibrosis samples [25–27]. Our results indicate that these can be selectively inhibited, and thus prevent 
overgrowth of B. cepacia and P. aeruginosa which often cause severe, and sometimes fatal, lung 
infections in these patients. A second potential application of our work would be for detection of 
Salmonella spp. in the clinic. This is due to the relatively weak inhibitory levels (>8 mg/L) displayed 
by our compounds against these organisms in contrast to the more effective inhibition against the 
growth of E. coli (<4 mg/L). This is clinically useful as E. coli often overgrow Salmonella spp. when 
isolated from stool samples [5]. A further potential application of such compounds is the inhibition 
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of Enterococcus spp. facilitating the isolation of Listeria monocytogenes and pathogenic streptococci e.g., 
Streptococcus pyogenes. 
In this paper we present preliminary microbiology data to identify novel compounds that may 
prove useful as novel selective agents in diagnostic culture media. A major limitation of our data is 
that only 1 or 2 examples of any particular species have been tested and susceptibility (or resistance) 
may not be uniformly demonstrated across all strains of a particular species. The utility of these 
compounds can only be proven in subsequent studies by testing large numbers of strains from each 
relevant species and large numbers of clinical samples to see if the isolation of target pathogens may 
be enhanced. However, the fact that such utility as selective agents has been demonstrated for other 
peptide mimetics based on fosfalin provides encouragement that such agents may ultimately prove 
useful [5,28]. 
3. Materials and Methods 
All commercially available reagents and solvents were acquired from Sigma-Aldrich, Fluka, 
Alfa-aesar, Fluorochem, Fischer Scientific and Bachem and used without further purification unless 
otherwise stated. All deuterated solvents were purchased from Goss Scientific and Apollo Scientific. 
Solvents were dried using the solvent purification system, PureSolv 400-5-MD, which was purchased 
from Innovative Technology (currently known as Inert) (Amesbury, MA, USA). Hydrogenation was 
performed using series 4560 mini reactors, acquired from Parr Instruments (Moline, Il, USA). Column 
chromatography was performed using Silica 60A (35–70 or 70–200 micron) Davisil® chromatography 
grade (Merck, Loughborough, UK). Thin layer chromatography was performed on Merck TLC Silica 
Gel 60 F254 (Loughborough, UK) or Fluka Silca (Dorset, UK) on TLC Alu foils. Melting points were 
recorded using a Reichart-Kofler (Staffordshire, UK) hot stage microscope apparatus and are 
uncorrected. Infrared spectra were recorded in the range 4000–550 cm−1 using a Perkin Elmer 
Spectrum BX FT-IR spectrophotometer (Waltham, MA, USA). NMR spectra were acquired using a 
Bruker Ultrashield 300 spectrometer (Billerica, MA, USA) at 300 MHz for 1H spectra, 75 MHz for 13C 
spectra, 121 MHz for 31P-1H decoupled spectra and 282 MHz for 19F-1H decoupled spectra. NMR data 
was analyzed by MestReNova (Mestrelab Research, Santiago de Compostela, Spain). Low-resolution 
mass spectra were obtained from a Bruker Esquire 3000plus analyzer (Billerica, MA, USA) using an 
electrospray source in either positive or negative ion mode. High-resolution mass spectra were 
acquired from Thermo Scientific LTQ Orbitrap XL (Waltham, MA, USA) using an electrospray source 
in either positive or negative ion mode. Elemental analyses were performed using an Exeter 
Analytical CE-440 Elemental Analyzer (Coventry, UK). The LC column, ACE Excel 5 Super C18 (150 
× 4.6 mm) and Eclipse Plus C18 (50 × 2.1 mm) were acquired from HICHROM (Reading, UK) and 
Agilent (Waldbronn, Germany), respectively. Elemental and purity by LC-MS were performed on 
final compounds or compounds which analytical data are not available in literature. 
3.1. Synthetic Procedures 
3.1.1. General IBCF/NMM Peptide Coupling Method 
In 100 mL one neck round-bottomed flask A, Cα-protected amine salt (1.0 equiv) or phosphonate 
ester protected amine salt (when L-Met was used) was dissolved in dry DCM or dry THF (25–50 mL) 
and cooled to −5 °C in an ice/brine bath. To this was added N,N-diisopropylethylamine, DIPEA (1.5 
equiv) or N-methyl morpholine, NMM (1.0 equiv) (when β-Cl-L-Ala was used). In 250 mL one neck 
round-bottomed flask B, Nα-protected amino acid (1.0 equiv) was dissolved in dry THF (25–50 mL) 
and to this was added N-methyl morpholine, NMM (1.5 equiv or 1.0 equiv when β-Cl-L-Ala moiety 
was involved) and isobutyl chloroformate (1.0 equiv) while stirring at −5 °C. The Flask B solution was 
stirred for 2–3 h at −5 °C, after which time the neutralized Cα-protected or phosphonate ester 
protected amine solution in Flask A was then added. The resulting mixture was stirred at −5 °C for 
10mins and then room temperature overnight (16–18 h). Work-up procedure: the mixture was filtered 
and filtrate was concentrated in vacuo to afford a crude product, which was dissolved in DCM and 
washed with 10 %w/v citric acid (2 × 30 mL), followed by 10 %w/v potassium carbonate (30 mL) and 
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finally water (30 mL). The organic layer was dried over magnesium sulfate, filtered, concentrated in 
vacuo, and purified by column chromatography using an appropriate solvent system to afford the 
product of interest. 
3.1.2. Removal of Benzyl Ester Protecting Group 
Cα-Benzyl ester amino acid or peptide was dissolved in methanol and to this was added 5%–
10% palladium on carbon (10 mol %). The mixture was stirred at 3.5 bar pressure of hydrogen at room 
temperature overnight (16–18 h). The catalyst was filtered using Celite and the filtrate was 
concentrated in vacuo to afford the product of interest. 
3.1.3. Removal of N-tert-Butoxycarbonyl Protecting Group 
N-tBoc amino acid or peptide was dissolved in excess of a solution of dry 2M HCl in diethyl 
ether. The resulting solution was stirred at room temperature for 2 days to afford a crude solid, which 
was collected by filtration and washed with excess dry diethyl ether to afford the product of interest. 
3.1.4. Removal of tert-Butoxycarbonyl and Diethyl Phosphonate Ester Protecting Groups 
Phosphonopeptide containing N-tert-butoxycarbonyl and O,O-diethyl phosphonate ester was 
dissolved in 35 %wt HBr in acetic acid (10 equiv) and stirred at room temperature overnight (16–18 
h). Dry diethyl ether was added to afford a precipitation. The resulting mixture was stored in the 
freezer overnight (16–18 h) to result in more precipitation. The solvent was decanted and remaining 
crude solid was triturated (× 3) with dry diethyl ether. The resulting solid was dissolved in dry 
methanol and propylene oxide was added in excess to afford a crude precipitation, which was 
recrystallized from the appropriate solvent system to afford the product of interest.  
 
 
1-Aminoethylphosphonic Acid or D/L-fosfalin (2-DL). To suspension of N-phenylthiourea (100.0 mmol, 
15.2 g) in glacial acetic acid (50 mL), acetaldehyde (130.0 mmol, 7.40 mL) was added dropwise, 
followed by triphenyl phosphite (100.0 mmol, 27.0 mL). The mixture was stirred at room temperature 
for 5 mins, then refluxed at 80 °C for 1 h until a clear solution was obtained. A mixture of glacial acetic 
acid (5 mL) and hydrochloric acid (37%, 50 mL) was added and the reaction was refluxed overnight. 
The solution was cooled to room temperature and concentrated in vacuo to afford a brown slurry. 
Absolute ethanol (150 mL) was added while stirring and the resulting off-white solid was collected 
by filtration and dried in a desiccator containing phosphorus(V) oxide. The crude solid was 
recrystallized from hot water/ethanol to afford 2-DL as white crystals, as a mixture of enantiomers 
(12.2 g, 98 mmol, 98%); m.p. 271–274 °C (sublim); ῡmax/cm−1 2910 (br OH), 1532 (NH bend), 1143 (P=O), 
1035 (P-O-C), 930 (P-OH); 1H NMR (300 MHz, D2O) δH 1.40 (3H, dd, 3JH-P = 14.7 Hz, 3JH-H = 7.2 Hz, 
CH3), 3.33 (1H, m, CH); 13C NMR (75 MHz, D2O) δC 13.5 (d, 2JC-P = 2.6 Hz, CH3), 44.7 (d, 1JC-P = 144.2 
Hz, CH); 31P-1Hdecoup NMR (121 MHz, D2O) δP 14.2; m/z (ESI) calcd for (C2H9NO3P)+, MH+: 126.0, found 
126.1; CHN (Found: C, 19.45; H, 6.48; N, 11.18. C2H8NO3P requires C, 19.21; H, 6.45; N, 11.20%). (The 
1H- and 13C-NMR spectra may be found within the Supplementary Materials). 
 
Diethyl (1-(2,2,2-trifluoroacetamido)ethyl)phosphonate or trifluoroacetyl-D/L-Fos diethyl ester (8). 1-
Aminoethylphosphonic acid (2-DL) (51.7 mmol, 6.5 g) was added to a mixture of trifluoroacetic acid 
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(65.3 mmol, 5 mL) and trifluoroacetic anhydride (177.4 mmol, 25 mL). The solution was stirred and 
refluxed at 60 °C for 1 h, then cooled to room temperature and triethyl orthoformate (901.8 mmol, 150 
mL) was added dropwise. The solution was refluxed at 110 °C for 2 h, then cooled to room 
temperature. The solution was concentrated in vacuo to afford a brown solid, which was re-dissolved 
in DCM and purified by column chromatography using a gradient elution (DCM (100) to 
DCM/MeOH (95:5)) to give 8 as an off-white solid, a mixture of enantiomers (11.4 g, 41.0 mmol, 80%); 
m.p. 101–103 °C (sublim) (lit. m.p. 101–102 °C) [29]; ῡmax/cm−1 3202 (NH), 1715 (C=O), 1565 (NH bend), 
1210 (P=O), 1011 (P-O-C), 968 (P-O-C); 1H NMR (300 MHz, CDCl3) δH 1.24 (3H, t, 3JH-H = 7.2 Hz, 
OCH2CH3), 1.27 (3H, t, 3JH-H = 7.2 Hz, OCH2CH3), 1.38 (3H, dd, 3JH-P = 16.5 Hz, 3JH-H = 7.2 Hz, CH3-2), 
4.06 (4H, m, 2 × OCH2CH3), 4.39 (1H, m, CH-1), 8.00 (1H, d, 3JH-H = 6.0 Hz, NH); 13C NMR (75 MHz, 
CDCl3) δC 14.8 (CH3-2), 16.2 (d, 3JC-P = 2.3 Hz, OCH2CH3), 16.3 (d, 3JC-P = 2.3 Hz, OCH2CH3), 41.8 (d, 1JC-
P = 159.1 Hz, CH-1), 62.8 (d, 2JC-P = 7.0 Hz, OCH2CH3), 63.2 (d, 2JC-P = 7.1 Hz, OCH2CH3), 115.9 (q, 1JC-F 
= 285.8 Hz, CF3), 156.9 (q, 2JC-F = 5.8 Hz, C=O); 31P-1Hdecoup NMR (121 MHz, CDCl3) δP 23.0; 19F-1Hdecoup 
NMR (282 MHz, CDCl3) δP −75.5; m/z (ESI) calcd for (C8H16F3NO4P)+, MH+: 278.1, found 278.1. 
 
Diethyl 1-aminoethylphosphonate or D/L-Fos diethyl ester (9). Diethyl (1-(2,2,2-
trifluoroacetamido)ethyl)phosphonate (8) (20.0 mmol, 5.6 g) was dissolved in ethanol (200 ml) and 
excess sodium borohydride (200.0 mmol, 7.7 g) was added slowly with stirring. The resulting mixture 
was stirred at room temperature for 1 h, then heated at reflux for 4 h. The mixture was cooled to room 
temperature and the solvent was removed in vacuo to afford a white solid, which was dissolved in 
saturated NaHCO3 (96 g/L) (60 mL) with the addition of 10% aqueous K2CO3 (20 mL). The product 
was extracted into DCM (6 × 30 mL) and dried over MgSO4. The filtrate was concentrated in vacuo to 
afford a pale yellow liquid and purified by column chromatography using a gradient elution (DCM 
(100) to DCM/MeOH (90:10)) to afford 9 as a yellow liquid, a mixture of enantiomers (3.5 g, 19.3 
mmol, 97%); ῡmax/cm−1 3431 (NH), 1215 ( P=O), 1020 (P-O-C), 967 (P-O-C); 1H NMR (300 MHz, CDCl3) 
δH 1.26 (6H, t, 3JH-H = 7.2 Hz, 2 × OCH2CH3), 1.34 (3H, dd, 3JH-P = 17.7 Hz, 3JH-H = 7.2 Hz, CH3-2), 1.68 
(2H, br, NH2), 3.02–3.12 (1H, m, CH-1), 4.06–4.17 (4H, m, 2 × OCH2CH3); 13C NMR (75 MHz, CDCl3) 
δC 16.4 (OCH2CH3), 16.5 (OCH2CH3), 17.2 (CH3-2), 44.2 (d, 1JC-P = 148.5 Hz, CH-1), 62.1 (d, 2JC-P = 7.5 
Hz, OCH2CH3), 62.1 (d, 2JC-P = 7.5 Hz, OCH2CH3); 31P-1Hdecoup NMR (121 MHz, CDCl3) δP 29.6; HRMS 
(NSI) calcd for (C6H17NO3P)+, MH+: 204.0760, found 204.0762. LCMS purity >95% (C-18 reversed 
phase, MeOH–H2O). 
 
(S)-Benzyl 2-((S)-2-((tert-butoxycarbonyl)amino)pentanamido) propanoate or Boc-L-Nva-L-Ala-OBzl (16a). 
General peptide coupling method was followed, using Boc-L-Nva-OH (15a) (10.0 mmol, 2.17 g) in 
dry THF and L-alanine benzyl ester p-tosylic acid (10.0 mmol, 3.52 g) in dry DCM. The yellow crude 
liquid was purified by column chromatography (40–60 petrol/ethyl acetate (7:3)) to give 16a as an off-
white solid (2.40 g, 6.3 mmol, 63%); m.p. 60–63 °C; ῡmax/cm−1 3332 (NH), 1743 (C=O), 1655 (br C=O), 
1527 (NH bend), 1245 (C-O), 1162 (C-O); 1H NMR (300 MHz, CDCl3) δH 0.83 (3H, t, 3JH-H = 9.0 Hz, CH3-
7’’), 1.25–1.31 (2H, m, CH2-7’), 1.34 (3H, d, 3JH-H = 6.0 Hz, CH3-3), 1.36 (9H, s, C(CH3)3), 1.42–1.54 (1H, 
m, CHa/b-7), 1.64–1.73 (1H, m, CHa/b-7), 4.02 (1H, m, CH-6), 4.54 (1H, pentet, 3JH-H = 6.0 Hz, CH-2), 4.96 
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(1H, d, 3JH-H = 9.0 Hz, NH-8), 5.07 (1H, d, 2JH-H = 12.0 Hz, OCHa/bAr), 5.12 (1H, d, 2JH-H = 12.0 Hz, 
OCHa/bAr), 6.56 (1H, d, 3JH-H = 6.0 Hz, NH-4), 7.27 (5H, m, 5 × CHAr); 13C NMR (75 MHz, CDCl3) δC 
12.7 (CH3-7’’), 17.3 (CH3-3), 17.8 (CH2-7’), 27.3 (C(CH3)3), 33.7 (CH2-7), 47.1 (CH-2), 53.4 (CH-6), 
66.1(OCH2Ar), 79.0 (C(CH3)3), 127.1-127.6 (CHAr), 134.3 (CHAr quat.), 154.6 (C=O-9), 170.8 (C=O-5), 
171.5 (C=O-1); HRMS (NSI) calcd for (C20H31N2O5)+, MH+: 379.2227, found 379.2222; CHN (Found: C, 
63.75; H, 8.37; N, 7.86. C20H30N2O5 requires C, 63.47; H, 7.99; N, 7.40%). 
 
(S)-Benzyl 2-(2-((tert-butoxycarbonyl)(methyl)amino)acetamido) propanoate or Boc-Sar-L-Ala-OBzl (16b). 
General peptide coupling method was followed, using Boc-Sar-OH (15b) (15.0 mmol, 2.84 g) in dry 
THF and L-alanine benzyl ester p-tosylic acid (15.0 mmol, 5.27 g) in dry DCM. The yellow crude liquid 
was purified by column chromatography (40–60petrol/ethyl acetate (1:1)) to give 16b as a colourless 
liquid (3.93 g, 11 mmol, 75%); ῡmax/cm−1 3311 (NH), 1742 (C=O), 1670 (C=O), 1666 (C=O), 1536 (NH 
bend), 1242 (C-O), 1145 (C-O); 1H NMR (300 MHz, CDCl3) δH 1.35 (3H, t, 3JH-H = 6.0 Hz, CH3-3), 1.39 
(9H, s, C(CH3)3), 2.85 (3H, s, CH3-8), 3.72 (1H, d, 2JH-H = 15.0 Hz, CHa/b-6), 3.88 (1H, d, 2JH-H = 15.0 Hz, 
CHa/b-6), 4.58 (1H, pentet, 3JH-H = 6.0 Hz, CH-2), 5.08 (1H, d, 2JH-H = 12.0 Hz, OCHa/bAr), 5.13 (1H, d, 2JH-
H = 12.0 Hz, OCHa/bAr), 6.51 (1H, br, NH-4), 7.25-7.29 (5H, m, 5 × CHAr); 13C NMR (75 MHz, CDCl3) δC 
17.5 (CH3-3), 27.3 (C(CH3)3), 34.7 (CH3-8), 47.0 (CH-2), 52.1 (CH2-6), 66.2 (OCH2Ar), 79.8 (C(CH3)3), 
127.1–127.6 (CHAr), 134.3 (CHAr quat.), 155.0 (C=O-9), 167.9 (C=O-5), 171.5 (C=O-1); HRMS (NSI) calcd 
for (C18H27N2O5)+, MH+: 351.1914, found 351.1916. LCMS purity >95% (C-18 reversed phase, MeOH–
H2O). 
 
Tert-butyl ((2S)-1-((-1-(diethoxyphosphoryl)ethyl)amino)-1-oxopropan-2-yl)carbamate or Boc-L-Ala-D/L-Fos 
diethyl ester (19d). General peptide coupling method was followed, using Boc-L-Ala-OH (15d) (10.0 
mmol, 1.90 g) in dry THF and diethyl 1-aminoethylphosphonate (9) (10.0 mmol, 1.84 g) in dry THF. 
The pale yellow crude syrup was purified by column chromatography, using 100% DCM and 
increasing to 95:5 DCM/methanol, to afford 19d as an off-white solid composed of 2 diastereoisomers, 
Boc-L-Ala-L-Fos diethyl ester and Boc-L-Ala-D-Fos diethyl ester (2.49 g, 7.1 mmol, 71%); m.p. 102–105 
°C; ῡmax/cm−1 3280 (NH), 1710 (C=O), 1652 (C=O), 1556 (NH bend), 1229 (P=O), 1173 (C-O), 1013 (P-O-
C), 973 (P-O-C); 1H NMR (300 MHz, CDCl3) δH 1.23–1.43 (12H, m, CH3-2, CH3-6, 2 × OCH2CH3), 1.44 
(9H, s, C(CH3)3), 4.06–4.23 (5H, m, 2 × OCH2CH3, CH-5), 4.40–4.52 (1H, m, CH-1), 5.12 (0.5H, d, 3JH-H 
= 1.5 Hz, NH-7), 5.14 (0.5H, d, 3JH-H = 1.5 Hz, NH-7), 6.72 (0.5H, d, 3JH-H = 2.3 Hz, NH-3), 6.74 (0.5H, d, 
3JH-H = 2.3 Hz, NH-3); 13C NMR (75 MHz, CDCl3) δC 15.6 (CH3-2), 16.3 (d, 3JC-P = 3.0 Hz, OCH2CH3), 16.4 
(d, 3JC-P = 2.3 Hz, OCH2CH3), 16.5 (d, 3JC-P = 3.0 Hz, OCH2CH3), 16.6 (d, 3JC-P = 2.3 Hz, OCH2CH3), 18.4 
(CH3-6), 28.3 (C(CH3)3), 40.8 (d, 1JC-P = 156.8 Hz, CH-1), 41.0 (d, 1JC-P = 156.8 Hz, CH-1), 50.0 (CH-5), 
62.4 (d, 2JC-P = 6.8 Hz, OCH2CH3), 62.5 (d, 2JC-P = 6.8 Hz, OCH2CH3), 62.6 (d, 2JC-P = 6.8 Hz, OCH2CH3), 
62.8 (d, 2JC-P = 6.8 Hz, OCH2CH3), 80.0 (C(CH3)3), 155.2 (C=O-8), 172.1 (C=O-4); 31P-1Hdecoup NMR (121 
MHz, CDCl3) δP 25.2; HRMS (NSI) calcd for (C17H35N3O7P)+, MH+: 424.2207, found 424.2200; CHN 
(Found: C, 48.22; H, 8.58; N, 7.87. C14H29N2O6P requires C, 47.92; H, 8.30; N, 7.95%). 
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(S)-2-((S)-2-((Tert-butoxycarbonyl)amino)pentanamido) propanoic acid or Boc-L-Nva-L-Ala-OH (17a). 
Deprotection of benzyl ester was followed, using (S)-benzyl 2-((S)-2-((tert-
butoxycarbonyl)amino)pentanamido)propanoate (16a) (6.0 mmol, 2.27 g) to afford 17a as a white 
solid (1.66 g, 5.7 mmol, 96.0%); m.p. 55–58 °C (decomp.); ῡmax/cm−1 3500–3000 (br, OH), 3300 (NH), 
1688 (br C=O), 1655 (C=O), 1522 (NH bend), 1245 (C-O), 1164 (C-O); 1H NMR (300 MHz, CDCl3) δH 
0.85 (3H, t, 3JH-H = 9.0 Hz, CH3-7’’), 1.27–1.31 (5H, m, CH3-3, CH2-7’), 1.39 (9H, s, C(CH3)3), 1.48–1.53 
(1H, m, CHa/b-7), 1.67–1.71 (1H, m, CHa/b-7), 4.10 (1H, m, CH-6), 4.50 (1H, m, CH-2), 5.27 (1H, m, NH-
8), 6.93 (1H, m, NH-4), 8.87 (1H, br, OH); 13C NMR (75 MHz, CDCl3) δC 13.7 (CH3-7’’), 18.0 (CH3-3), 
18.8 (CH2-7’), 28.3 (C(CH3)3), 34.5 (CH2-7), 48.1 (CH-2), 54.3 (CH-6), 80.4 (C(CH3)3), 156.0 (C=O-9), 
172.5 (C=O-5), 175.5 (C=O-1); HRMS (NSI) calcd for (C13H25N2O5)+, MH+: 289.1758, found 289.1758; 
CHN (Found: C, 54.18; H, 8.78; N, 9.62. C13H24N2O5 requires C, 54.15; H, 8.39; N, 9.72%). 
 
(S)-Benzyl 2-(2-((tert-butoxycarbonyl)(methyl)amino)acetamido) propanoic acid or Boc-Sar-L-Ala-OH (17b). 
Deprotection of benzyl ester was followed, using (S)-benzyl 2-(2-((tert-
butoxycarbonyl)(methyl)amino)acetamido) propanoate (16b) (10.0 mmol, 3.51 g) to afford 17b as a 
colorless syrup (2.50 g, 9.6 mmol, 96%); ῡmax/cm−1 3301 (NH), 2961 (broad OH), 1736 (C=O), 1664 (br 
C=O), 1542 (NH bend), 1241 (C-O), 1147 (C-O); 1H NMR (300 MHz, CDCl3) δH 1.36 (3H, t, 3JH-H = 6.0 
Hz, CH3-3), 1.39 (9H, s, C(CH3)3), 2.89 (3H, s, CH3-8), 3.72 (1H, d, 2JH-H = 18.0 Hz, CHa/b-6), 3.98 (1H, d, 
2JH-H = 18.0 Hz, CHa/b-6), 4.57 (1H, m, CH-2), 6.96 (1H, m, NH-4), 7.26 (1H, br, OH); 13C NMR (75 MHz, 
CDCl3) δC 17.2 (CH3-3), 27.3 (C(CH3)3), 46.8 (CH-2), 49.6 (CH3-8), 52.1 (CH2-6), 80.6 (C(CH3)3), 155.5 
(C=O-9), 168.3 (C=O-5), 174.1 (C=O-1); HRMS (NSI) calcd for (C11H19N2O5)-, MH−: 259.1299, found 
259.1295. LCMS purity >95% (C-18 reversed phase, MeOH-H2O). 
 
(2S)-1-((1-(Diethoxyphosphoryl)ethyl)amino)-1-oxopropan-2-aminium chloride or L-Ala-D/L-Fos diethyl ester 
hydrochloride (20d). Deprotection of tert-butoxycarbonyl was followed, using tert-butyl ((2S)-1-((-1-
(diethoxyphosphoryl)ethyl)amino)-1-oxopropan-2-yl)carbamate (19d) (6.0 mmol, 2.13 g). The off-
white hygroscopic crude solid was washed with petrol to afford 20d as a pale green solid composed 
of 2 diastereoisomers, L-Ala-L-Fos diethyl ester hydrochloride and L-Ala-D-Fos diethyl ester 
hydrochloride (1.46 g, 5.1 mmol, 84%); m.p. 60–63 °C; ῡmax/cm−1 2986 (NH+), 1673 (C=O), 1555 (NH 
bend), 1212(P=O), 1017 (P-O-C), 970 (P-O-C); 1H NMR (300 MHz, CD3OD) δH 1.29-1.44 (9H, m, 2 × 
OCH2CH3, CH3-2), 1.51 (3H, d, 3JH-H = 6.0 Hz, CH3-6), 3.90-3.98 (1H, m, CH-5), 4.08-4.22 (4H, m, 2 × 
OCH2CH3), 4.28-4.47 (1H, m, CH-1); 13C NMR (75 MHz, CD3OD) δC 13.7 (CH3-2), 14.0 (CH3-2), 15.4 (2 
× OCH2CH3), 16.3 (CH3-6), 41.1 (d, 1JC-P = 158.3 Hz, CH-1), 41.4 (d, 1JC-P = 158.3 Hz, CH-1), 48.8 (CH-5), 
48.9 (CH-5), 62.7–63.0 (2 × OCH2CH3), 169.0 (C=O-4); 31P-1Hdecoup NMR (121 MHz, CDCl3) δP 29.0, 29.1; 
HRMS (NSI) calcd for (C9H22N2O4P)+, M+: 253.1312, found 253.1316. LCMS purity >95% (C-18 reversed 
phase, MeOH-H2O). 




yl)carbamate or Boc-L-Nva-L-Ala-D/L-Fos diethyl ester (18a). General peptide coupling method was 
followed, using (S)-2-((S)-2-((tert-butoxycarbonyl)amino)pentanamido)propanoic acid (17a) (5.0 
mmol, 1.45 g) in dry THF and diethyl 1-aminoethylphosphonate (9) (4.8 mmol, 0.87 g) in dry THF. 
The white crude solid was purified by column chromatography using 100% DCM, increasing to 90:10 
DCM/methanol, to afford 18a as a white solid composed of 2 diastereoisomers, Boc-L-Nva-L-Ala-L-
Fos diethyl ester and Boc-L-Nva-L-Ala-D-Fos diethyl ester (1.70 g, 3.8 mmol, 78%); m.p. 165–168 °C; 
ῡmax/cm−1 3267 (NH), 1708 (C=O), 1638 (br C=O), 1537 (NH bend), 1227 (P=O), 1165 (C-O), 1019 (P-O-
C), 966 (P-O-C); 1H NMR (300 MHz, CDCl3) δH 0.85 (3H, t, 3JH-H = 9.0 Hz, CH3-10’’), 1.18–1.34 (14H, m, 
2 × OCH2CH3, CH3-2, CH3-6, CH2-10’), 1.37 (9H, s, C(CH3)3), 1.47–1.54 (1H, m, CHa/b-10), 1.65–1.73 
(1H, m, CHa/b-10), 3.98–4.12 (5H, m, 2 × OCH2CH3, CH-9), 4.33–4.44 (1H, m, CH-1), 4.48–4.54 (1H, m, 
CH-5), 5.19 (0.5H, d, 3JH-H = 6.0 Hz, NH-11), 5.23 (0.5H, d, 3JH-H = 6.0 Hz, NH-11), 6.78 (0.5H, d, 3JH-H = 
6.0 Hz, NH-7), 6.87 (0.5H, d, 3JH-H = 6.0 Hz, NH-7), 7.15 (0.5H, d, 3JH-H = 9.0 Hz, NH-3), 7.23 (0.5H, d, 
3JH-H = 9.0 Hz, NH-3); 13C NMR (75 MHz, CDCl3) δC 12.7 (CH3-10’’), 14.4 (CH3-2), 14.5 (CH3-2), 15.3 
(OCH2CH3), 15.4 (OCH2CH3), 15.5 (OCH2CH3), 15.6 (OCH2CH3), 17.6 (CH3-6), 17.7 (CH3-6), 17.8 (CH2-
10’), 17.9 (CH2-10’), 27.3 (C(CH3)3), 33.8 (CH2-10), 33.9 (CH2-10), 39.9 (d, 1JP-C = 157.5 Hz, CH-1), 40.0 
(d, 1JP-C = 156.8 Hz, CH-1), 47.7 (CH-5), 47.9 (CH-5), 53.5 (CH-9), 53.5 (CH-9), 61.5 (d, 2JC-P = 7.5 Hz, 
OCH2CH3), 61.6 (d, 2JC-P = 7.5 Hz, OCH2CH3), 61.7 (d, 2JC-P = 7.5 Hz, OCH2CH3), 61.9 (d, 2JC-P = 7.5 Hz, 
OCH2CH3), 78.9 (C(CH3)3), 154.7 (C=O-12), 170.6 (C=O-4 or C=O-8), 170.7 (C=O-4 or C=O-8), 171.0 
(C=O-4 or C=O-8), 171.1 (C=O-4 or C=O-8); 31P-1Hdecoup NMR (121 MHz, CDCl3) δP 25.0, 25.1; HRMS 
(NSI) calcd for (C19H39N3O7P)+, MH+: 452.2520, found 452.2518; CHN (Found: C, 50.74; H, 8.55; N, 9.51. 
C19H38N3O7P requires C, 50.54; H, 8.48; N, 9.31%).  
 
Tert-butyl (2-(((2S)-1-((1-(diethoxyphosphoryl)ethyl)amino)-1-oxopropan-2-yl)amino)-2-
oxoethyl)(methyl)carbamate or Boc-Sar-L-Ala-D/L-Fos (18b). General peptide coupling method was 
followed, using (S)-benzyl 2-(2-((tert-butoxycarbonyl)(methyl)amino)acetamido)propanoic acid 
(17b) (6.0 mmol, 1.57 g) in dry THF and diethyl 1-aminoethylphosphonate (9) (6.0 mmol, 1.10 g) in 
dry THF. The yellow crude liquid was purified by column chromatography, using 100% DCM and 
increasing to 90:10 DCM/methanol, to afford 18b as a colorless liquid composed of 2 
diastereoisomers, Boc-Sar-L-Ala-L-Fos diethyl ester and Boc-Sar-L-Ala-D-Fos diethyl ester (1.60 g, 3.8 
mmol, 63%); ῡmax/cm−1 3270 (NH), 1700 (br C=O), 1655 (C=O), 1545 (NH bend), 1225 (P=O), 1149 (C-
O), 1018 (P-O-C), 966 (P-O-C); 1H NMR (300 MHz, CDCl3) δH 1.19–1.34 (12H, m, CH3-2, CH3-6, 2 × 
OCH2CH3), 1.40 (9H, s, C(CH3)3), 2.87 (3H, s, CH3-11), 3.72 (0.5H, d, 2JH-H = 15.0 Hz, CHa/b-9), 3.78 
(0.5H, d, 2JH-H = 15.0 Hz, CHa/b-9), 3.81 (0.5H, d, 2JH-H = 15.0 Hz, CHa/b-9), 3.87 (0.5H, d, 2JH-H = 15.0 Hz, 
CHa/b-9), 4.00–4.11 (4H, m, 2 × OCH2CH3), 4.35-4.43 (1H, m, CH-1), 4.47–4.52 (1H, m, CH-5), 6.67 (1H, 
d, 3JH-H = 9.0 Hz, NH-7), 6.98 (0.5H, d, 3JH-H = 9.0 Hz, NH-3), 7.15 (0.5H, d, 3JH-H = 9.0 Hz, NH-3); 13C 
NMR (75 MHz, CDCl3) δC 15.5 (CH3-2), 15.5 (CH3-2), 16.3 (d, 3JP-C = 3.0 Hz, OCH2CH3), 16.4 (d, 3JP-C = 
3.0 Hz, OCH2CH3), 18.7 (CH3-6), 28.3 (C(CH3)3), 35.8 (CH3-11), 41.0 (d, 1JP-C = 157.5 Hz, CH-1), 48.5 
(CH-5), 53.0 (CH2-9), 62.5 (d, 2JP-C = 6.8 Hz, OCH2CH3), 62.6 (d, 2JP-C = 6.8 Hz, OCH2CH3), 62.7 (d, 2JP-C 
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= 6.8 Hz, OCH2CH3), 62.9 (d, 2JP-C = 6.8 Hz, OCH2CH3), 80.7 (C(CH3)3), 156.0 (C=O-12), 171.5 (C=O-4 
or C=O-8), 171.6 (C=O-4 or C=O-8); 31P-1Hdecoup NMR (121 MHz, CDCl3) δP 25.0, 25.1; HRMS (NSI) 




oxobutan-2-yl)carbamate or Boc-L-Met-L-Ala-D/L-Fos diethyl ester (18c). General peptide coupling method 
was followed, using Boc-L-Met-OH (15c) (3.4 mmol, 0.88 g) in dry THF and (2S)-1-((1-
(diethoxyphosphoryl)ethyl)amino)-1-oxopropan-2-aminium chloride (20d) (3.4 mmol, 0.97 g) in dry 
DCM. The yellow crude solid was purified by column chromatography (DCM/MeOH (95:5)) to give 
18c as an off-white solid composed of 2 diastereoisomers, Boc-L-Met-L-Ala-L-Fos diethyl ester and 
Boc-L-Met-L-Ala-D-Fos diethyl ester (0.53 g, 1.1 mmol, 32%); m.p. 172–176 °C; ῡmax/cm−1 3272 (NH), 
1708 (C=O), 1673 (C=O), 1637 (C=O), 1530 (NH bend), 1226 (P=O), 1165 (C-O), 1020 (P-O-C), 976 (P-
O-C); 1H NMR (300 MHz, CDCl3) δH 1.16–1.36 (12H, m, CH3-2, CH3-6, 2 × OCH2CH3), 1.36 (9H, s, 
C(CH3)3), 1.82–2.01 (2H, m, CH2-10), 2.04 (3H, s, CH3-10’’), 2.49 (2H, dd, 3JH-H = 9.0 Hz, 3.0 Hz, CH2-
10’), 4.00–4.12 (4H, m, 2 × OCH2CH3), 4.16–4.26 (1H, m, CH-9), 4.33–4.43 (1H, m, CH-1), 4.45–4.53 
(1H, m, CH-5), 5.40 (0.5H, d, 3JH-H = 9.0 Hz, NH-11), 5.44 (0.5H, d, 3JH-H = 6.0 Hz, NH-11), 6.85 (0.5H, d, 
3JH-H = 6.0 Hz, NH-7), 6.92 (0.5H, d, 3JH-H = 6.0 Hz, NH-7), 7.07 (0.5H, d, 3JH-H = 9.0 Hz, NH-3), 7.16 (0.5H, 
d, 3JH-H = 9.0 Hz, NH-3); 13C NMR (75 MHz, CDCl3) δC 14.2 (CH3-2), 14.3 (CH3-2), 14.5 (CH3-10’’), 14.6 
(CH3-10’’), 15.4 (d, 3JC-P = 3.0 Hz, OCH2CH3), 15.4 (d, 3JC-P = 2.3 Hz, OCH2CH3), 15.5 (d, 3JC-P = 3.0 Hz, 
OCH2CH3), 15.5 (d, 3JC-P = 2.3 Hz, OCH2CH3), 17.7 (CH3-6), 27.3 (C(CH3)3), 29.2 (CH2-10’), 29.3 (CH2-
10’), 30.8 (CH2-10), 30.9 (CH2-10), 39.9 (d, 1JC-P = 156.8 Hz, CH-1), 40.0 (d, 1JC-P = 156.8 Hz, CH-1), 47.9 
(CH-5), 48.0 (CH-5), 52.6 (CH-9), 61.5 (d, 2JC-P = 6.8 Hz, OCH2CH3), 61.6 (d, 2JC-P = 6.8 Hz, OCH2CH3), 
61.7 (d, 2JC-P = 6.8 Hz, OCH2CH3), 61.9 (d, 2JC-P = 6.8 Hz, OCH2CH3), 79.1 (C(CH3)3), 154.6 (C=O-12), 
170.3 (C=O-4 or C=O-8), 170.4 (C=O-4 or C=O-8), 170.5 (C=O-4 or C=O-8), 170.6 (C=O-4 or C=O-8); 31P-
1Hdecoup NMR (121 MHz, CDCl3) δP 25.0, 25.1; HRMS (NSI) calcd for (C19H39N3O7PS)+, MH+: 484.2241, 
found 484.2228. LCMS purity >95% (C-18 reversed phase, MeOH–H2O). 
 
(1-((S)-2-((S)-2-Aminopentanamido)propanamido)ethyl) phosphonic acid or L-Nva-L-Ala-D/L-Fos (21a). The 
tert-butoxycarbonyl and diethyl ester protecting groups of tert-butyl ((2S)-1-(((2S)-1-((1-
(diethoxyphosphoryl)ethyl)amino)-1-oxopropan-2-yl)amino)-1-oxopentan-2-yl)carbamate (18a) (1.6 
mmol, 0.72 g) were removed. The pale green crude solid was recrystallised from hot water/acetone 
to give 21a as a pale green solid composed of 2 diastereoisomers, L-Nva-L-Ala-L-Fos and L-Nva-L-
Ala-D-Fos (0.22 g, 0.75 mmol, 47%); m.p. 207–210 °C (decomp.); ῡmax/cm−1 3280 (NH+), 3500-2900 (br 
OH), 1643 (br C=O), 1552 (NH bend), 1149 (P=O), 1037 (P-O-C), 922 (P-OH); 1H NMR (300 MHz, D2O) 
δH 0.96 (3H, t, 3JH-H = 7.1 Hz, CH3-10’’), 1.27-1.32 (3H, d, 3JH-H = 6.8 Hz, CH3-2), 1.40-1.42 (3H, m, CH3-
6), 1.40–1.42 (2H, m, CH2-10’), 1.88–1.86 (2H, m, CH2-10), 4.00–4.02 (2H, m, CH-1, CH-9), 4.34–4.39 
(1H, m, CH-5); 13C NMR (75 MHz, D2O) δC 13.4 (CH3-10’’), 16.0 (CH3-2), 17.1 (CH3-6), 17.2 (CH3-6), 
18.1 (CH2-10’), 18.2 (CH2-10’), 33.5 (CH2-10), 33.6 (CH2-10), 50.5 (CH-5), 50.8 (CH-5), 53.5 (CH-1, CH-
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9), 170.4 (C=O-8), 170.6 (C=O-8),174.7 (C=O-4); 31P-1Hdecoup NMR (121 MHz, CDCl3) δP 18.5; HRMS 
(NSI) calcd for (C10H23N3O5P)+, MH+: 296.1370, found 296.1373. LCMS purity >95% (C-18 reversed 
phase, MeOH-H2O). (The LCMS chromatogram and conditions may be found within the 
Supplementary Materials). 
 
(1-((S)-2-(2-(Methylamino)acetamido)propanamido)ethyl) phosphonic acid or Sar-L-Ala-D/L-Fos (21b). The 
tert-butoxycarbonyl and diethyl ester protecting groups of (1-((S)-2-((S)-2-
aminopropanamido)propanamido)ethyl)phosphonic acid (18b) (3.3 mmol, 1.40 g) were removed. 
The pale green crude solid was recrystallised from hot water/ethanol to give 21b as a pale green solid 
composed of 2 diastereoisomers, Sar-L-Ala-L-Fos and Sar-L-Ala-D-Fos (0.45 g, 1.7 mmol, 51%); m.p. 
241–245 °C (decomp.); ῡmax/cm−1 3289 (NH+), 3500–2900 (br OH), 1632 (br C=O), 1556 (NH bend), 1174 
(P=O), 1059 (P-O-C), 919 (P-OH); 1H NMR (300 MHz, D2O) δH 1.14–1.57 (6H, m, CH3-2, CH3-6), 2.74 
(3H, s, CH3-11), 3.84–4.07 (3H, m, CH2-9, CH-1), 4.32–4.58 (1H, m, CH-5); 13C NMR (75 MHz, D2O) δC 
15.4 (CH3-2), 16.8 (CH3-6), 32.9 (CH3-11), 43.9 (d, 1JP-C = 148.5 Hz, CH-1), 49.4 (CH2-9), 50.0 (CH-5), 
166.0 (C=O-8), 173.7 (C=O-4); 31P-1Hdecoup NMR (121 MHz, CDCl3) δP 19.2; HRMS (NSI) calcd for 
(C8H19N3O5P)+, MH+: 268.1057, found 268.1016; LCMS purity >95% (C-18 reversed phase, MeOH–
H2O). (The LCMS chromatogram and conditions may be found within the Supplementary Materials). 
 
 
(1-((S)-2-((S)-2-Amino-4-(methylthio)butanamido) propanamido)ethyl)phosphonic acid or L-Met-L-Ala-D/L-
Fos (21c). The tert-butoxycarbonyl and diethyl ester protecting groups of tert-butyl ((2S)-1-(((2S)-1-
((1-(diethoxyphosphoryl)ethyl)amino)-1-oxopropan-2-yl)amino-4-(methylthio)-1-oxobutan-2-
yl)carbamate (18c) (0.9 mmol, 0.43 g) were removed. The green crude solid was recrystallised from 
hot water/ethanol to give 21c as a pale green solid composed of 2 diastereoisomers, L-Met-L-Ala-L-
Fos and L-Met-L-Ala-D-Fos (0.13 g, 0.41 mmol, 46%); m.p. 214–217 °C (decomp.); ῡmax/cm−1 3263 (NH+), 
2834 (broad OH), 1641 (br C=O), 1552 (NH bend), 1150 (P=O), 1041 (P-O-C), 919 (P-OH); 1H NMR (300 
MHz, D2O) δH 1.29–1.33 (3H, m, CH3-2), 1.42 (3H, d, 3JH-H = 6.0 Hz, CH3-6), 2.15 (3H, s, CH3-10’’), 2.20 
(2H, m, CH2-10), 2.62 (2H, m, CH2-10’), 4.05 (1H, m, CH-1), 4.14 (1H, m, CH-9), 4.39–4.41 (1H, m, CH-
5); 13C NMR (75 MHz, D2O) δC 16.9 (CH3-10’’), 18.4 (CH3-2), 19.5 (CH3-6), 19.6 (CH3-6), 32.8 (CH2-10’), 
33.0 (CH2-10’), 30.7 (CH2-10), 31.0 (CH2-10), 44.4 (CH-1), 52.9 (CH-5), 53.0 (CH-5), 55.0 (CH-9), 176.1 
(C=O-4, C=O-8); 31P-1Hdecoup NMR (121 MHz, CDCl3) δP 20.7; HRMS (NSI) calcd for (C10H23N3O5PS)+, 
MH+: 328.1091, found 328.1094; LCMS purity >95% (C-18 reversed phase, MeOH-H2O). (The LCMS 
chromatogram and conditions may be found within the Supplementary Materials). 
 
(S)-Benzyl 2-((tert-butoxycarbonyl)amino)-3-hydroxy propanoate or Boc-L-Ser-OBzl (11). Boc-L-Serine (10) 
(20 mmol, 4.10 g) and 1,8-diazabicyclo [5.4.0]undec-7-ene (DBU) (30 mmol, 4.5 mL) were dissolved in 
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a round-bottom flask containing dry benzene (80 mL), followed by the addition of benzyl bromide 
(30 mmol, 3.60 mL). Caution: Benzene is a known carcinogen. The solution was stirred overnight at 
room temperature under nitrogen and later the solvent was removed under reduced pressure to 
afford an off-white residue. Ethyl acetate (100 mL) was added, the flask contents were sonicated and 
then washed with 1M HCl (50 mL) and brine (2 × 50 mL). The organic layer was dried over MgSO4, 
filtered, concentrated in vacuo and purified by column chromatography (petrol/ethyl acetate (1:1)) to 
give 11 as a white solid (5.24 g, 17.7 mmol, 89%); m.p. 61–63 °C (lit. m.p. 59–60 °C) [30]; ῡmax/cm−1 3416 
(NH, OH), 1756 (C=O), 1666 (C=O), 1522 (NH bend), 1200 (C-O), 1154 (C-O); 1H NMR (300 MHz, 
CDCl3) δH 1.36 (9H, s, C(CH3)3), 2.17 (1H, br, OH), 3.82 (1H, dd, 2JH-H = 11.1 Hz, 3JH-H = 3.6 Hz, CHa/b-
3), 3.90 (1H, dd, 2JH-H = 11.1 Hz, 3JH-H = 3.9 Hz, CHa/b-3), 4.33 (1H, m, CH-2), 5.11 (1H, d, 2JH-H = 12.3 Hz, 
OCHa/bAr), 5.16 (1H, d, 2JH-H = 12.3 Hz, OCHa/bAr), 5.40 (1H, br, NH-4), 7.27 (5H, m, 5 × CHAr); 13C 
NMR (75 MHz, CDCl3) δC 27.1 (C(CH3)3), 54.7 (CH-2), 62.3 (CH2-3), 66.2 (OCH2Ar), 79.1 (C(CH3)3), 
127.0 (2 × CHAr), 127.3 (CHAr), 127.4 (2 × CHAr), 134.1 (CHAr quat.), 153.0 (C=O-5), 170.7 (C=O-1); m/z 
(ESI) calcd for (C15H21NNaO5)+, MNa+: 318.3, found 318.2. (The 1H-NMR spectrum may be found 
within the Supplementary Materials). 
 
(R)-Benzyl 2-((tert-butoxycarbonyl)amino)-3-chloropropanoate or Boc-β-Cl-L-Ala-OBzl (12). (S)-Benzyl 2-
((tert-butoxycarbonyl)amino)-3-hydroxypropanoate (11) (15 mmol, 4.43 g) was dissolved in dry DCM 
(40 mL), followed by the addition of trichloroacetonitrile (30 mmol, 3 ml). The solution was stirred at 
room temperature for 2 h. To this solution, triphenylphosphine (30 mmol, 7.87 g) in dry DCM (50 
mL) was added slowly. The resulting solution was stirred overnight at room temperature under 
nitrogen; brine (100 mL) was added to quench the reaction. The organic layer was washed with brine 
(3 × 100 mL), dried over MgSO4, filtered and concentrated in vacuo to afford an orange residue. The 
residue was purified by column chromatography (petrol/ethyl acetate (7:3)) to give 12 as a white solid 
(3.53 g, 11.2 mmol, 75%); m.p. 55–58 °C; ῡmax/cm−1 3364 (NH), 1725 (C=O), 1680 (C=O), 1519 (NH bend), 
1208 (C-O), 1158 (C-O); 1H NMR (300 MHz, CDCl3) δH 1.38 (9H, s, C(CH3)3), 3.78 (1H, dd, 2JH-H = 11.2 
Hz, 3JH-H = 3.2 Hz, CHa/b-3), 3.92 (1H, dd, 2JH-H = 11.3 Hz, 3JH-H = 3.0 Hz, CHa/b-3), 4.67 (1H, m, CH-2), 
5.13 (1H, d, 2JH-H = 12.2 Hz, OCHa/bAr), 5.18 (1H, d, 2JH-H = 12.2 Hz, OCHa/bAr), 5.37 (1H, d, 3JH-H = 7.5 
Hz, NH-4), 7.29 (5H, m, 5 × CHAr); 13C NMR (75 MHz, CDCl3) δC 28.3 (C(CH3)3), 45.5 (CH2-3), 54.5 
(CH-2), 67.8 (OCH2Ar), 80.5 (C(CH3)3), 128.4 (CHAr), 128.6 (CHAr), 128.7 (CHAr), 134.9 (CHAr quat.), 
155.0 (C=O-5), 169.0 (C=O-1); m/z (ESI) calcd for (C15H20ClNNaO4)+, MNa+: 336.1 (35Cl), 338.1 (37Cl), 
found 336.2 (35Cl), 338.2 (37Cl); CHN (Found: C, 57.71; H, 6.46; N, 4.38. C15H20ClNO4 requires C, 57.42; 
H, 6.42; N, 4.46%). (The mass spectrum may be found within the Supplementary Materials). 
 
(R)-2-((Tert-butoxycarbonyl)amino)-3-chloropropanoic acid or Boc-β-Cl-L-Ala-OH (13). Deprotection of 
benzyl ester was followed, using (R)-benzyl 2-((tert-butoxycarbonyl)amino)-3-chloropropanoate (12) 
(7.0 mmol, 2.20 g) to afford 13 as an off-white solid (1.52 g, 6.78 mmol, 97%); m.p. 125–128 °C (lit. m.p. 
127–129 °C) [15]; ῡmax/cm−1 3434 (NH), 2973 (br OH), 1752 (C=O), 1735 (C=O), 1519 (NH bend), 1159 
(C-O), 1148 (C-O); 1H NMR (300 MHz, CDCl3) δH 1.40 (9H, s, C(CH3)3), 3.80 (1H, dd, 2JH-H = 12.0 Hz, 
3JH-H = 3.0 Hz, CHa/b-3), 3.95 (1H, dd, 2JH-H = 12.0 Hz, 3JH-H = 3.0 Hz, CHa/b-3), 4.70 (1H, m, CH-2), 5.42 
(1H, d, 3JH-H = 7.2 Hz, NH-4), 9.03 (1H, br, OH); 13C NMR (75 MHz, CDCl3) δC 27.1 (C(CH3)3), 44.0 
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(CH2-3), 53.1 (CH-2), 79.8 (C(CH3)3), 154.2 (C=O-5), 172.1 (C=O-1); m/z (ESI) calcd for 
(C8H14ClNNaO4)+, MNa+: 246.1 (35Cl), 248.1 (37Cl), found 246.1 (35Cl), 248.1 (37Cl). 
 
(R)-1-(Benzyloxy)-3-chloro-1oxopropan-2-aminium chloride or β-Cl-L-Ala-OBzl hydrochloride (14). 
Deprotection of tert-butoxycarbonyl was followed, using (R)-benzyl 2-((tert-butoxycarbonyl)amino)-
3-chloropropanoate (12) (15 mmol, 4.71 g). The white crude solid was filtered and washed by diethyl 
ether to give 14 as a white solid (3.47 g, 13.4 mmol, 93%); m.p. 145 °C (sub); ῡmax/cm−1 2841 (NH+), 1750 
(C=O), 1231 (C-O); 1H NMR (300 MHz, D2O) δH 4.06 (1H, dd, 2JH-H = 15.0 Hz, 3JH-H = 6.0 Hz, CHa/b-3), 
4.20 (1H, dd, 2JH-H = 15.0 Hz, 3JH-H = 6.0 Hz, CHa/b-3), 4.70 (1H, t, 3JH-H = 6.0 Hz, CH-2), 5.29 (1H, d, 2JH-H 
= 12.0 Hz, OCHa/bAr), 5.37 (1H, d, 2JH-H = 12.0 Hz, OCHa/bAr), 7.42-7.47 (5H, m, 5 × CHAr); 13C NMR (75 
MHz, D2O) δC 41.8 (CH2-3), 54.0 (CH-2), 69.1 (OCH2Ar), 128.6–129.1 (CHAr), 134.5 (CHAr quart.), 167.0 
(C=O-1); m/z (ESI) calcd for (C10H13ClNO2), M+: 214.1 (35Cl), 216.1 (37Cl), found 214.1 (35Cl), 216.1 (37Cl); 
CHN (Found: C, 47.16; H, 5.43; N, 5.43. C10H13Cl2NO2∙0.2H2O requires C, 47.34; H, 5.32; N, 5.52%). 
 
(R)-Benzyl 2-((S)-2-((tert-butoxycarbonyl)amino)pentanamido)-3-chloropropanoate or Boc-L-Nva-β-chloro-L-
Ala-OBzl (22a). General peptide coupling method was followed, using Boc-L-Nva-OH (15a) (6.0 
mmol, 1.31 g) in dry THF and (R)-1-(benzyloxy)-3-chloro-1oxopropan-2-aminium chloride (14) (5.4 
mmol, 1.36 g) in dry DCM. The yellow crude liquid was purified by column chromatography (40-60 
petrol/ethyl acetate (7:3)) to give 22a as a white solid (1.74 g, 4.2 mmol, 78%); m.p. 95–98 °C; ῡmax/cm−1 
3327 (NH), 1743 (C=O), 1688 (C=O), 1653 (C=O), 1518 (NH bend), 1206 (C-O), 1169 (C-O); 1H NMR 
(300 MHz, CDCl3) δH 0.92 (3H, t, 3JH-H = 9.0 Hz, CH3-7’’), 1.32-1.43 (2H, m, CH2-7’), 1.45 (9H, s, C(CH3)3), 
1.52–1.65 (1H, m, CHa/b-7), 1.75-1.82 (1H, m, CHa/b-7), 3.89 (1H, dd, 2JH-H = 12.0 Hz, 3JH-H = 3.0 Hz, CHa/b-
3), 3.99 (1H, dd, 2JH-H = 12.0 Hz, 3JH-H = 3.0 Hz, CHa/b-3), 4.11–4.15 (1H, m, CH-6), 4.96–5.00 (2H, m, CH-
2, NH-8), 5.20 (1H, d, 2JH-H = 12.0 Hz, OCHa/bAr), 5.25 (1H, d, 2JH-H = 12.0 Hz, OCHa/bAr), 6.97 (1H, d, 
3JH-H = 6.0 Hz, NH-4), 7.33–7.37 (5H, m, 5 x CHAr); 13C NMR (75 MHz, CDCl3) δC 12.7 (CH3-7’’), 17.8 
(CH2-7’), 27.3 (C(CH3)3), 33.4 (CH2-7), 43.8 (CH2-3), 52.2 (CH-2), 53.4 (CH-6), 67.0 (OCH2Ar), 79.3 
(C(CH3)3), 127.4 (CHAr), 127.6 (CHAr), 127.7 (CHAr), 133.8 (CHAr quat.), 154.5 (C=O-9), 167.5 (C=O-1), 
171.2 (C=O-5); HRMS (NSI) calcd for (C20H30ClN2O5)+, MH+ : 413.1838 (35Cl), 415.1809 (37Cl), found 
413.1837 (35Cl), 415.1807 (37Cl); CHN (Found: C, 58.49; H, 7.22; N, 6.81. C20H29ClN2O5 requires C, 58.18; 
H, 7.08; N, 6.78%). 
 
(R)-Benzyl 2-(2-((tert-butoxycarbonyl)(methyl)amino) acetamido)-3-chloropropanoate or Boc-Sar-β-chloro-L-
Ala-OBzl (22b). General peptide coupling method was followed, using Boc-Sar-OH (15b) (13.0 mmol, 
2.46 g) in dry THF and (R)-1-(benzyloxy)-3-chloro-1oxopropan-2-aminium chloride (14) (13.3 mmol, 
3.34 g) in dry DCM. The yellow crude liquid was purified by column chromatography (40–60 
petrol/ethyl acetate (7:3)) to give 22b as a light yellow syrup (3.63 g, 9.4 mmol, 73%); ῡmax/cm−1 3302 
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(NH), 1747 (C=O), 1686 (br C=O), 1522 (NH bend), 1175 (C-O), 1148 (C-O); 1H NMR (300 MHz, CDCl3) 
δH 1.40 (9H, s, C(CH3)3), 2.87 (3H, s, NCH3-8), 3.80 (1H, d, 2JH-H = 15.0 Hz, CHa/b-6), 3.82 (1H, d, 2JH-H = 
15.0 Hz, CHa/b-6), 3.83 (1H, dd, 2JH-H = 12.0 Hz, 3JH-H = 3.0 Hz, CHa/b-3), 3.94 (1H, dd, 2JH-H = 12.0 Hz, 3JH-
H = 3.0 Hz, CHa/b-3), 4.91–4.96 (1H, m, CH-2), 5.13 (1H, d, 2JH-H = 12.0 Hz, OCHa/bAr), 5.18 (1H, d, 2JH-H 
= 12.0 Hz, OCHa/bAr), 6.97 (1H, d, 3JH-H = 6.0 Hz, NH-4), 7.26–7.30 (5H, m, 5 x CHAr); 13C NMR (75 
MHz, CDCl3) δC 28.2 (C(CH3)3), 35.6 (NCH3-8), 44.9 (CH2-3), 53.0 (CH2-6), 53.0 (CH-2), 68.0 (OCH2Ar), 
81.0 (C(CH3)3), 128.4 (CHAr), 128.6 (CHAr), 128.7 (CHAr), 134.8 (CHAr quat.), 154.5 (C=O-9), 168.4 (C=O-
1), 169.4 (C=O-5); HRMS (NSI) calcd for (C18H26ClN2O5)+, MH+: 385.1525 (35Cl), 387.1496 (37Cl), found 
385.1527 (35Cl), 387.1498 (37Cl). LCMS purity >95% (C-18 reversed phase, MeOH–H2O). 
 
Tert-butyl ((2R)-3-chloro-1-((1-(diethoxyphosphoryl)ethyl) amino)-1-oxopropan-2-yl)carbamate or Boc-β-
chloro-L-Ala-D/L-Fos diethyl ester (19e). General peptide coupling method was followed, using (R)-2-
((tert-butoxycarbonyl)amino)-3-chloropropanoic acid (13) (6.0 mmol, 1.34 g) in dry THF and diethyl 
1-aminoethylphosphonate (9) (6.0 mmol, 1.09 g) in dry THF. The light yellow crude liquid was 
purified by column chromatography, using 100% petrol and increasing to 100% ethyl acetate, to 
afford 19e as colorless syrup composed of 2 diastereoisomers, Boc-β-Cl-L-Ala-L-Fos diethyl ester and 
Boc-β-Cl-L-Ala-D-Fos diethyl ester (2.03 g, 5.2 mmol, 88%); ῡmax/cm−1 3261 (NH), 1713 (C=O), 1670 
(C=O), 1517 (NH bend), 1225 (P=O), 1164 (C-O), 1020 (P-O-C), 970 (P-O-C); 1H NMR (300 MHz, CDCl3) 
δH 1.15–1.46 (9H, m, CH3-2, 2 × OCH2CH3), 1.47 (9H, s, C(CH3)3), 3.74 (1H, dd, 2JH-H = 12.0 Hz, 3JH-H = 
6.0 Hz, CHa/b-6), 4.00 (1H, dd, 2JH-H = 12.0 Hz, 3JH-H = 6.0 Hz, CHa/b-6), 4.06–4.22 (4H, m, 2 × OCH2CH3), 
4.40–4.56 (2H, m, CH-1, CH-5), 5.46 (0.5H, d, 3JH-H = 6.0 Hz, NH-3 or NH-7), 5.48 (0.5H, d, 3JH-H = 9.0 
Hz, NH-3 or NH-7), 7.01 (0.5H, m, NH-3 or NH-7), 7.09 (0.5H, m, NH-3 or NH-7); 13C NMR (75 MHz, 
CDCl3) δC 15.6 (CH3-2), 15.7 (CH3-2), 16.3 (d, 3JC-P = 1.5 Hz, OCH2CH3), 16.4 (d, 3JC-P = 2.3 Hz, 
OCH2CH3), 16.4 (d, 3JC-P = 1.5 Hz, OCH2CH3), 16.4 (d, 3JC-P = 2.3 Hz, OCH2CH3), 28.2 (C(CH3)3), 41.2 (d, 
1JC-P = 157.5 Hz, CH-1), 41.3 (d, 1JC-P = 157.5 Hz, CH-1), 55.2 (CH2-6), 55.3 (CH-5), 62.6 (d, 2JC-P = 6.8 Hz, 
OCH2CH3), 62.6 (d, 2JC-P = 6.8 Hz, OCH2CH3), 63.0 (d, 2JC-P = 6.8 Hz, OCH2CH3), 63.0 (d, 2JC-P = 6.8 Hz, 
OCH2CH3), 80.8 (C(CH3)3), 155.0 (C=O-8), 168.3 (C=O-4); 31P-1Hdecoup NMR (121 MHz, CDCl3) δP 24.7, 
24.8; HRMS (NSI) calcd for (C14H28ClN2O6P), MH+: 409.1266 (35Cl), 411.1237 (37Cl), found 409.1258 
(35Cl), 411.1231 (37Cl). LCMS purity >95% (C-18 reversed phase, MeOH-H2O). 
 
(R)-2-((S)-2-((tert-Butoxycarbonyl)amino)pentanamido)-3-chloropropanoic acid or Boc-L-Nva-β-chloro-L-
Ala-OH (23a). Deprotection of benzyl ester was followed, using (R)-benzyl 2-((S)-2-((tert-
butoxycarbonyl)amino)pentanamido)-3-chloropropanoate (22a) (5.8 mmol, 2.41 g) to afford 23a as a 
light yellow solid (1.81 g, 5.61 mmol, 96%); m.p. 60–63 °C; ῡmax/cm−1 3312 (br OH), 2963 (NH), 1655 
(br C=O), 1509 (NH bend), 1161 (C-O); 1H NMR (300 MHz, DMSO) δH 0.85 (3H, t, 3JH-H = 9.0 Hz, CH3-
7’’), 1.24–1.34 (2H, m, CH2-7’), 1.38 (9H. s, C(CH3)3), 1.42–1.52 (1H, m, CHa/b-7), 1.54–1.59 (1H, m, 
CHa/b-7), 3.34 (1H, br, OH), 3.84 (1H, dd, 2JH-H = 12.0 Hz, 3JH-H = 6.0 Hz, CHa/b-3), 3.91 (1H, dd, 2JH-H = 
12.0 Hz, 3JH-H = 6.0 Hz, CHa/b-3), 3.95–4.02 (1H, m, CH-6), 4.62–4.67 (1H, m, CH-2), 6.92 (1H, d, 3JH-H = 
9.0 Hz, NH-8), 8.07 (1H, d, 3JH-H = 9.0 Hz, NH-4); 13C NMR (75 MHz, CDCl3) δC 14.1 (CH3-7’’), 19.1 
(CH2-7’), 28.6 (C(CH3)3), 34.4 (CH2-7), 45.1 (CH2-3), 53.6 (CH-2), 54.5 (CH-6), 78.5 (C(CH3)3), 155.8 
(C=O-9), 170.6 (C=O-5), 173.0 (C=O-1); m/z (ESI) calcd for (C13H23ClN2NaO5)+, MNa+: 345.1 (35Cl), 347.1 
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(37Cl), found 345.2 (35Cl), 347.2 (37Cl); CHN (Found: C, 48.67; H, 7.51; N, 8.42. C13H23ClN2O5 requires 
C, 48.37; H, 7.18; N, 8.68%). 
 
(R)-2-(2-((tert-butoxycarbonyl)(methyl)amino)acetamido)-3-chloropropanoic acid or Boc-Sar-β-chloro-L-Ala-
OH (23b). Deprotection of benzyl ester was followed, using (R)-benzyl 2-(2-((tert-
butoxycarbonyl)(methyl)amino)acetamido)-3-chloropropanoate (22b) (6.2 mmol, 2.40 g) to afford 
23b as an off-white solid (1.81 g, 6.1 mmol, 99%); m.p. 89–91 °C; ῡmax/cm−1 3342 (NH), 2982 (br OH), 
1734 (C=O), 1672 (C=O), 1644 (C=O), 1524 (NH bend), 1152 (C-O); 1H NMR (300 MHz, CDCl3) δH 1.47 
(9H. s, C(CH3)3), 2.99 (3H, s, NCH3-8), 3.81–4.17 (4H, m, CH2-6, CH2-3), 5.01 (1H, m, CH-2), 7.07 (1H, 
br, NH-4), 7.45 (1H, br, OH); 13C NMR (75 MHz, CDCl3) δC 28.3 (C(CH3)3), 36.1 (NCH3-8), 44.5 (CH2-
3), 53.0 (CH2-6 and CH-2), 81.8 (C(CH3)3), 156.8 (C=O-9), 169.5 (C=O-1 and C=O-5); m/z (ESI) calcd for 
(C11H19ClN2NaO5)+, MNa+: 317.1 (35Cl), 319.1 (37Cl), found 317.1 (35Cl), 319.1 (37Cl); CHN (Found: C, 
43.98; H, 6.69; N, 9.53. C11H19ClN2O5∙0.3H2O requires C, 44.02; H, 6.58; N, 9.33%). 
 
(2R)-3-Chloro-1-((1-(diethoxyphosphoryl)ethyl)amino)-1-oxopropan-2-aminium chloride or β-Cl-L-
Ala-D/L-Fos diethyl ester hydrochloride (20e). Deprotection of tert-butoxycarbonyl was followed, 
using ((2R)-3-chloro-1-((1-(diethoxyphosphoryl)ethyl)amino)-1-oxopropan-2-yl)carbamate (19e) (6.7 
mmol, 2.59 g). The off-white hygroscopic crude solid was washed with petrol to afford 20e as a pale 
green solid composed of 2 diastereoisomers, β-Cl-L-Ala-L-Fos diethyl ester hydrochloride and β-Cl-
L-Ala-D-Fos diethyl ester hydrochloride (1.51 g, 4.7 mmol, 70%); m.p. 129–133 °C (decomp.); ῡmax/cm−1 
3204 (NH+), 1687 (C=O), 1562 (NH bend), 1204 (P=O), 1010 (P-O-C), 961 (P-O-C); 1H NMR (300 MHz, 
D2O) δH 1.28 (3H, t, 3JH-H = 6.0 Hz, OCH2CH3), 1.29 (3H, t, 3JH-H = 6.0 Hz, OCH2CH3), 1.37 (3H, dd, 3JP-H 
= 18.0 Hz, 3JH-H = 6.0 Hz, CH3-2), 3.92–4.04 (2H, m, CH2-6), 4.07-4.21 (4H, m, 2 × OCH2CH3), 4.38–4.48 
(2H, m, CH-1, CH-5); 13C NMR (75 MHz, D2O) δC 13.7 (CH3-2), 14.0 (CH3-2), 15.7 (OCH2CH3), 15.7 
(OCH2CH3), 41.7 (d, 1JP-C = 158.3 Hz, CH-1), 42.0 (d, 1JP-C = 157.5 Hz, CH-1), 42.4 (CH2-6), 53.7 (CH-5), 
53.8 (CH-5), 64.3 (d, 2JP-C = 6.8 Hz, OCH2CH3), 64.5 (d, 2JP-C = 6.8 Hz, OCH2CH3), 165.7 (C=O-4), 165.8 
(C=O-4); 31P-1Hdecoup NMR (121 MHz, CDCl3) δP 26.1, 26.2; HRMS (NSI) calcd for (C9H21ClN2O4P)+, M+: 
287.0922 (35Cl), 289.0892 (37Cl), found 287.0922 (35Cl), 289.0890 (37Cl). LCMS purity >95% (C-18 
reversed phase, MeOH–H2O). 
 
Tert-butyl ((2S)-1-(((2R)-3-chloro-1-((1-(diethoxyphosphoryl)-ethyl)amino)-1-oxopropan-2-yl)amino)-1-
oxopentan-2-yl)carbamate or Boc-L-Nva-β-chloro-L-Ala-D/L-Fos diethyl ester (24a). General peptide 
coupling method was followed, using (R)-2-((S)-2-((tert-butoxycarbonyl)amino)pentanamido)-3-
chloropropanoic acid (23a) (1.8 mmol, 0.58 g) in dry THF and diethyl 1-aminoethylphosphonate (9) 
(1.8 mmol, 0.33 g) in dry THF. The light yellow crude liquid was purified by column chromatography, 
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using ethyl acetate/methanol (96:4), to afford 24a as a white solid composed of 2 diastereoisomers, 
Boc-L-Nva-β-Cl-L-Ala-L-Fos diethyl ester and Boc-L-Nva-β-Cl-L-Ala-D-Fos diethyl ester (0.45 g, 0.93 
mmol, 52%); m.p. 196 °C (decomp); ῡmax/cm−1 3272 (NH), 1709 (C=O), 1680 (C=O), 1644 (C=O), 1530 
(NH bend), 1229 (P=O), 1165 (C-O), 1019 (P-O-C), 972 (P-O-C); 1H NMR (300 MHz, CDCl3) δH 0.86 
(1.5H, t, 3JH-H = 9.0 Hz, CH3-10’’), 0.88 (1.5H, t, 3JH-H = 9.0 Hz, CH3-10’’), 1.22–1.34 (11H, m, 2 × 
OCH2CH3, CH3-2, CH2-10’), 1.38 (9H, s, C(CH3)3), 1.53-1.59 (1H, m, CHa/b-10), 1.70–1.77 (1H, m, CHa/b-
10), 3.69 (1H, dd, 2JH-H = 12.0 Hz, 3JH-H = 6.0 Hz, CHa/b-6), 3.78-3.81 (1H, m, CH-9), 3.91 (1H, dd, 2JH-H = 
12.0 Hz, 3JH-H = 6.0 Hz, CHa/b-6), 3.97-4.13 (4H, m, 2 x OCH2CH3), 4.35-4.46 (1H, m, CH-1), 4.73-4.79 
(1H, m, CH-5), 4.97–5.03 (1H, m, NH-11), 7.01 (0.5H, d, 3JH-H = 9.0 Hz, NH-7), 7.09 (0.5H, d, 3JH-H = 9.0 
Hz, NH-7), 7.25 (0.5H, d, 3JH-H = 9.0 Hz, NH-3), 7.33 (0.5H, d, 3JH-H = 9.0 Hz, NH-3); 13C NMR (75 MHz, 
CDCl3) δC 12.7 (CH3-10’’), 14.5 (CH3-2), 15.3 (OCH2CH3), 15.4 (OCH2CH3), 15.5 (OCH2CH3), 15.6 
(OCH2CH3), 17.9 (CH2-10’), 18.0 (CH2-10’), 27.0 (C(CH3)3), 27.3 (C(CH3)3), 33.2 (CH2-10), 40.4 (d, 1JC-P = 
157.5 Hz, CH-1), 43.4 (CH2-6), 52.6 (CH-5), 52.8 (CH-5), 61.4 (d, 2JC-P = 6.8 Hz, OCH2CH3), 61.6 (d, 2JC-P 
= 6.8 Hz, OCH2CH3), 61.7 (d, 2JC-P = 6.8 Hz, OCH2CH3), 61.9 (d, 2JC-P = 6.8 Hz, OCH2CH3), 70.5 (CH-9), 
79.4 (C(CH3)3), 154.7 (C=O-12), 166.8 (C=O-4), 171.4 (C=O-8); 31P-1Hdecoup NMR (121 MHz, CDCl3) δP 
24.9, 25.0; HRMS (NSI) calcd for (C19H38ClN3O7P)+, MH+: 486.2130 (35Cl), 488.2102 (37Cl), found 
486.2124 (35Cl), 488.2098 (37Cl); CHN (Found: C, 46.61; H, 7.76; N, 8.31. C19H37ClN3O7P requires C, 
46.96; H, 7.67; N, 8.65%). 
 
Tert-butyl (2-(((2R)-3-chloro-1-((1-(diethoxyphosphoryl)ethyl) amino)-1-oxopropan-2-yl)amino)-2-
oxoethyl)(methyl)carbamate or Boc-Sar-β-chloro-L-Ala-D/L-Fos diethyl ester (24b). General peptide 
coupling method was followed, using (R)-2-(2-((tert-butoxycarbonyl)(methyl)amino)acetamido)-3-
chloropropanoic acid (23b) (5.5 mmol, 1.61 g) in dry THF and diethyl 1-aminoethylphosphonate (9) 
(6.0 mmol, 1.09 g) in dry THF. The light yellow crude liquid was purified by column chromatography, 
using DCM/methanol (95:5), to afford 24b as a light yellow syrup composed of 2 diastereoisomers, 
Boc-Sar-β-Cl-L-Ala-L-Fos diethyl ester and Boc-Sar-β-Cl-L-Ala-D-Fos diethyl ester (1.93 g, 4.21 mmol, 
76%); ῡmax/cm−1 3218 (NH), 1690 (C=O), 1665 (br C=O), 1518 (NH bend), 1224 (P=O), 1148 (C-O), 1018 
(P-O-C), 967 (P-O-C); 1H NMR (300 MHz, CDCl3) δH 1.11–1.35 (9H, m, 2 × OCH2CH3, CH3-2), 1.41 (9H, 
s, C(CH3)3), 2.90 (3H, s, CH3-11), 3.70–3.88 (4H, m, CH2-6, CH2-9), 4.02–4.13 (4H, m, 2 × OCH2CH3), 
4.36–4.47 (1H, m, CH-1), 4.78–4.82 (1H, m, CH-5), 6.94 (1H, m, NH-7), 7.36 (1H, m, NH-3); 13C NMR 
(75 MHz, CDCl3) δC 15.2 (CH3-2), 15.6 (CH3-2), 16.3 (OCH2CH3), 16.4 (OCH2CH3), 28.3 (C(CH3)3), 35.9 
(CH3-11), 41.2 (d, 1JC-P = 156.8 Hz, CH-1), 44.7 (CH2-6), 53.1 (CH2-9), 53.4 (CH-5), 62.7 (d, 2JC-P = 6.0 Hz, 
OCH2CH3), 63.0 (d, 2JC-P = 7.5 Hz, OCH2CH3), 81.0 (C(CH3)3), 152.3 (C=O-12), 167.7 (C=O-4 or C=O-8), 
169.4 (C=O-4 or C=O-8); 31P-1Hdecoup NMR (121 MHz, CDCl3) δP 24.7, 24.8; HRMS (NSI) calcd for 
(C16H34ClN3O7P)+, MH+: 480.1637 (35Cl), 482.1608 (37Cl), found 480.1642 (35Cl), 482.1612 (37Cl). LCMS 
purity >92% (C-18 reversed phase, MeOH-H2O). 
 
Tert-butyl ((2S)-1-(((2R)-3-chloro-1-((1-(diethoxyphosphoryl) ethyl)amino)-1-oxopropan-2-yl)amino)-4-
(methylthio)-1-oxobutan-2-yl) carbamate or Boc-L-Met-β-Cl-L-Ala-D/L-Fos diethyl ester (24c). General 
Molecules 2020, 25, 1557 20 of 25 
 
peptide coupling method was followed, using Boc-L-Met-OH (15c) (3.4 mmol, 0.85 g) in dry THF and 
(2R)-3-chloro-1-((1-(diethoxyphosphoryl)ethyl)amino)-1-oxopropan-2-aminium chloride (20e) (3.4 
mmol, 1.10 g) in dry DCM. The yellow crude liquid was purified by column chromatography 
(DCM/MeOH (95:5)) and recrystallized from diethyl ether/petrol to give 24c as a white solid 
composed of 2 diastereoisomers, Boc-L-Met-β-Cl-L-Ala-L-Fos diethyl ester and Boc-L-Met-β-Cl-L-Ala-
D-Fos diethyl ester (0.88 g, 1.7 mmol, 50%); m.p. 96–99 °C; ῡmax/cm−1 3278 (NH), 1709 (C=O), 1687 
(C=O), 1639 (C=O), 1523 (NH bend), 1228 (P=O), 1165 (C-O), 1018 (P-O-C), 970 (P-O-C); 1H NMR (300 
MHz, CDCl3) δH 1.17-1.36 (9H, m, CH3-2, 2 × OCH2CH3), 1.38 (9H, s, C(CH3)3), 1.87–2.03 (2H, m, CH2-
10), 2.04 (3H, s, CH3-10’’), 2.48–2.54 (2H, m, CH2-10’), 3.71 (1H, dd, 2JH-H = 12.0 Hz, 3JH-H = 6.0 Hz, CHa/b-
6), 3.88 (1H, dd, 2JH-H = 12.0 Hz, 3JH-H = 6.0 Hz, CHa/b-6), 3.99–4.13 (4H, m, 2 × OCH2CH3), 4.20 (1H, m, 
CH-9), 4.37–4.47 (1H, m, CH-1), 4.78–4.84 (1H, m, CH-5), 5.39 (0.5H, d, 3JH-H = 6.0 Hz, NH-11), 5.41 
(0.5H, d, 3JH-H = 6.0 Hz, NH-11), 7.15 (0.5H, d, 3JH-H = 6.0 Hz, NH-7), 7.24 (0.5H, d, 3JH-H = 6.0 Hz, NH-
7), 7.52 (1H, m, NH-3); 13C NMR (75 MHz, CDCl3) δC 14.3 (CH3-2), 14.4 (CH3-2), 14.5 (CH2-10’’), 15.3 
(OCH2CH3), 15.4 (OCH2CH3), 15.5 (OCH2CH3), 15.6 (OCH2CH3), 27.3 (C(CH3)3), 29.2 (CH2-10’), 29.3 
(CH2-10’), 30.2 (CH2-10), 30.4 (CH2-10), 40.3 (d, 1JP-C = 159.0 Hz, CH-1), 43.5 (CH2-6), 43.7 (CH2-6), 52.7 
(CH-5), 53.1 (CH-9), 61.6 (d, 2JP-C = 6.8 Hz, OCH2CH3), 61.7 (d, 2JP-C = 6.0 Hz, OCH2CH3), 62.0 (d, 2JP-C = 
6.8 Hz, OCH2CH3), 62.1 (d, 2JP-C = 7.5 Hz, OCH2CH3), 79.6 (C(CH3)3), 154.8 (C=O-12), 166.7 (C=O-4), 
166.8 (C=O-4), 170.7 (C=O-8), 170.8 (C=O-8); 31P-1Hdecoup NMR (121 MHz, CDCl3) δP 24.5, 24.8; HRMS 
(NSI) calcd for (C19H3HClN3O7PS)+, MH+: 518.1851 (35Cl), 520.1821 (37Cl), found 518.1842 (35Cl), 
520.1814 (37Cl); CHN (Found: C, 44.08; H, 7.47; N, 8.18. C19H37ClN3O7PS requires C, 44.06; H, 7.20; N, 
8.11%). 
 
(1-((R)-2-((S)-2-Ammoniopentanamido)-3-chloropropanamido) ethyl)phosphonic acid or L-Nva-β-chloro-L-
Ala-D/L-Fos (25a). The tert-butoxycarbonyl and diethyl ester protecting groups of tert-butyl ((2S)-1-
(((2R)-3-chloro-1-((1-(diethoxyphosphoryl)-ethyl)amino)-1-oxopropan-2-yl)amino)-1-oxopentan-2-
yl)carbamate (24a) (2.0 mmol, 0.99 g) were removed. The pale green crude solid was washed with 
diethyl ether to give 25a as a pale green solid composed of 2 diastereoisomers, L-Nva-β-Cl-L-Ala-L-
Fos and L-Nva-β-Cl-L-Ala-D-Fos (0.64 g, 1.94 mmol, 97%); m.p. 175 °C (sub); ῡmax/cm−1 3294 (NH+), 
3000 (br OH), 1668 (C=O), 1645 (C=O), 1538 (NH bend), 1132 (P=O), 1039 (P-O-C), 921 (P-OH); 1H 
NMR (300 MHz, D2O) δH 1.01 (3H, t, 3JH-H = 9.0 Hz, CH3-10’’), 1.30–1.37 (3H, br m, CH3-2), 1.44–1.54 
(2H, br m CH2-10’), 1.90–1.98 (2H, br m, CH2-10), 3.91–4.15 (4H, br m, CH2-6, CH-9, CH-1), 4.79 (1H, 
br m, CH-5); 13C NMR (75 MHz, D2O) δC 12.9 (CH3-10’’), 15.7 (CH3-2), 17.6 (CH2-10’), 33.0 (CH2-10), 
43.3 (CH2-6), 53.1 (CH-1 and CH-9), 55.0 (CH-5), 170.4 (C=O-4 and C=O-8); 31P-1Hdecoup NMR (121 
MHz, CDCl3) δP 18.5; HRMS (NSI) calcd for (C10H20ClN3O5P)-, MH-: 328.0835 (35Cl), 330.0805 (37Cl), 
found 328.0833 (35Cl), 330.0800 (37Cl). LCMS purity >95% (C-18 reversed phase, MeOH-H2O). (The 
LCMS chromatogram and conditions may be found within the Supplementary Materials). 
 
1-((R)-3-Chloro-2-(2-(methylammonio)acetamido) propanamido)ethyl)phosphonic acid or Sar-β-chloro-L-Ala-
D/L-Fos (25b). The tert-butoxycarbonyl and diethyl ester protecting groups of tert-butyl (2-(((2R)-3-
chloro-1-((1-(diethoxyphosphoryl)ethyl)amino)-1-oxopropan-2-yl)amino)-2-
oxoethyl)(methyl)carbamate (24b) (3.8 mmol, 1.74 g) were removed. The pale green crude solid was 
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recrystallised from hot water/ethanol to give 25b as an off-white solid composed of 2 
diastereoisomers, Sar-β-Cl-L-Ala-L-Fos and Sar-β-Cl-L-Ala-D-Fos (0.49 g, 1.61 mmol, 42%); m.p. 185-
188 °C (decomp.); ῡmax/cm−1 3287 (NH+), 3000 (br OH), 1657 (C=O), 1634 (C=O), 1552 (NH bend), 1172 
(P=O), 1054 (P-O-C), 919 (P-OH); 1H NMR (300 MHz, CD3OD) δH 1.24 (3H, dd, 3JH-P = 15.0 Hz, 3JH-H = 
6.0 Hz, CH3-2), 2.74 (3H, s, NCH3-11), 3.81–3.87 (2H, m, CH2-6), 3.93–3.94 (2H, m, CH2-9), 3.97–4.10 
(1H, m, CH-1), 4.79 (1H, m, CH-5); 13C NMR (75 MHz, CD3OD) δC 15.4 (CH3-2), 32.9 (NCH3-11), 43.6 
(CH2-6), 44.1 (d, 1JC-P = 148.5 Hz, CH-1), 49.5 (CH2-9), 54.6 (CH-5), 166.4 (C=O-4 or C=O-9), 166.9 (C=O-
4 or C=O-9); 31P-1Hdecoup NMR (121 MHz, CDCl3) δP 18.8; HRMS (NSI) calcd for (C8H18ClN3O5P)+, MH+: 
302.0667 (35Cl), 304.0638 (37Cl), found 302.0670 (35Cl), 304.0640 (37Cl). LCMS purity >95% (C-18 
reversed phase, MeOH-H2O). (The LCMS chromatogram and conditions may be found within the 
Supplementary Materials). 
 
(1-((R)-2-((S)-2-Ammonio-4-(methylthio)butanamido)-3-chloro propanamido)ethyl)phosphonic acid or L-Met-
β-Cl-L-Ala-D/L-Fos (25c). The tert-butoxycarbonyl and diethyl ester protecting groups of tert-butyl 
((2S)-1-(((2R)-3-chloro-1-((1-(diethoxyphosphoryl) ethyl)amino)-1-oxopropan-2-yl)amino)-4-
(methylthio)-1-oxobutan-2-yl)carbamate (24c) (1.4 mmol, 0.71 g) were removed. The green crude 
solid was recrystallised from hot water/ethanol to give 25c as a pale green solid composed of 2 
diastereoisomers, L-Met-β-Cl-L-Ala-L-Fos and L-Met-β-Cl-L-Ala-D-Fos (0.17 g, 0.48 mmol, 35%); m.p. 
175–179 °C (decomp.); ῡmax/cm−1 3264 (NH+), 2829 (broad OH), 1666(C=O), 1641 (C=O), 1546 (NH 
bend), 1149 (P=O), 1041 (P-O-C), 921 (P-OH); 1H NMR (300 MHz, D2O) δH 1.31 (3H, dd, 3JH-P = 15.0 Hz, 
3JH-H = 6.0 Hz, CH3-2), 2.13 (3H, s, CH3-10’’), 2.18–2.29 (2H, m, CH2-10), 2.63–2.69 (2H, m, CH2-10’), 
3.89 (1H, dd, 2JH-H = 12.0 Hz, 3JH-H = 6.0 Hz, CHa/b-6), 3.97 (1H, dd, 2JH-H = 12.0 Hz, 3JH-H = 6.0 Hz, CHa/b-
6), 4.01–4.13 (1H, m, CH-1), 4.22 (1H, br m, CH-9), 4.75–4.79 (1H, m, CH-5); 13C NMR (75 MHz, D2O) 
δC 16.9 (CH3-10’’), 17.0 (CH3-10’’), 18.4 (CH3-2), 31.1 (CH2-10’), 32.9 (CH2-10), 46.2 (CH2-6), 47.0 (d, 1JC-
P = 147.0 Hz, CH-1), 52.2 (CH-9), 52.3 (CH-9), 57.8 (CH-5), 58.0 (CH-5), 171.7 (C=O-4), 171.8 (C=O-4), 
172.3 (C=O-8); 31P-1Hdecoup NMR (121 MHz, CDCl3) δP 18.7; HRMS (NSI) calcd for (C10H21ClN3O5PS), 
MNa+: 384.0520 (35Cl), 386.0489 (37Cl), found 384.0523 (35Cl), 386.0491 (37Cl). LCMS purity >95% (C-18 
reversed phase, MeOH-H2O). (The LCMS chromatogram and conditions may be found within the 
Supplementary Materials). 
3.2. Microbiological Procedures 
3.2.1. Media Constituents 
L-Arginine, L-aspartic acid, L-cysteine, glycine, L-histidine, L-isoleucine, L-lysine, L-methionine, 
L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-valine, magnesium sulphate, 
haemin and D-(+)-glucose were purchased from Sigma Chemical Co. (Poole, UK). L-Tyrosine, uracil, 
guanine, cytosine, adenine, ammonium sulphate, potassium dihydrogen phosphate, saponin, and 
dipotassium hydrogen phosphate were acquired from BDH Merck Ltd. (Poole, England). Yeast 
extract was supplied by bioMérieux (Craponne, France) and bacteriological agar from Oxoid 
(Basingstoke, UK). Nicotinamide adenine dinucleotide (NAD) was obtained from Merck (Darmstadt, 
Germany) and heparinized horse blood from TCS Biosciences (Buckingham, UK). 
3.2.2. Microbiology Strains 
Microbial reference strains were obtained from National Collection of Type Cultures (NCTC) 
(Colindale, UK) and the American Type Culture Collection (ATCC) (Manassas, US). These included 
twelve Gram-negative bacteria: A. baumannii, B. cepacia, E. cloacae, E. coli (n = 2), K. pneumoniae, P. 
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rettgeri, P. aeruginosa, S. typhimurium, S. enteritidis, S. marcescens, and Y. enterocolitica; as well as seven 
Gram positive bacteria: E. faecalis, E. faecium, L. monocytogenes, S. epidermidis, S. aureus, methicillin 
resistant S. aureus (MRSA), and S. pyogenes. These 19 bacterial strains were maintained on Columbia 
agar. 
3.2.3. Preparation of Antagonist-free (AF) Medium 
The methodology utilized, which was reported by Atherton et al. [11], was adopted with slight 
modification. In this method, 1.5% (15 g/L) bacteriological agar and 0.5% (5 g/L) glucose were added 
to 880 mL deionized water. The resulting mixture was autoclaved at 121 °C for 15 min, followed by 
addition of 2 %v/v (20 mL/L) saponin-lysed horse blood, 25 mg/L hemin, 25 mg/L NAD and 100 mL 
of 10 x strength antagonist-free broth prepared as previously described [11]. The saponin-lysed blood 
was prepared by incubating 100 mL sterile hose blood at 37 ± 0.5 °C for 15 min, adding 5 mL 10% 
saponin and re-incubating for 15 min or longer to ensure completely blood lysis. The saponin-lysed 
blood was stored at 4 °C until used. The pH of medium was 7.0. 
3.2.4. Preparation of Media Containing Phosphonotripeptide Derivatives 
Each derivative was dissolved in sterile deionized water (SDW) and incorporated with AF-agar 
at a concentration range of 0.032–8 mg/L. A series of dilutions was performed to achieve the required 
concentration and then poured into the sterile Petri dishes. Plates containing AF-agar were also 
prepared without inhibitor. Solidified agar plates were placed in a warm cabinet (37 ± 0.5 °C) for 5 
min to dry the surface of the agar and then stored at 4 °C. 
3.2.5. Multiple Inoculation of Agar 
Each microbial strain was isolated from the respective Columbia agar after 18 h of incubation 
and suspended in SDW to a density equivalent to 0.5 McFarland units using a densitometer. One 
hundred microliters of each suspension was transferred into the corresponded wells of a multipoint 
inoculation device. One microliter of the bacterial suspension, equivalent to 1.5 × 105 organisms was 
applied as a spot by this instrument on the plates containing different phosphonotripeptide 
derivatives (as well as inhibit-free growth control plates). Nineteen different bacterial strains were 
applied on a plate and incubated for 22 h at 37 ± 0.5 °C. Un-inoculated AF-agar plates from the same 
batch of agar were incubated as a sterility check and a sterility check was also performed on the SDW 
used to make bacterial suspensions by culture of aliquots on Columbia agar. 
3.2.6. Determination of Minimum Inhibitory Concentration (MIC) 
After incubation, each plate was inspected for growth or inhibition of the inoculated spots. The 
minimum inhibitory concentration (MIC) was recorded as the lowest concentration of inhibitor to 
completely inhibit the growth of the test strain. Tests were performed in duplicate on separate 
occasions and in the vast majority of cases generated identical results. In a small minority of cases, 
results differed but were always within one double-dilution and this was always resolved by a third 
test. MIC values were only interpreted for any particular strain if growth on the inhibitor-free control 
plate was completely uninhibited and if sterility of the culture medium and diluent were validated. 
4. Conclusions 
Here we have disclosed the synthesis of six phosphonopeptide based inhibitors, all of which 
contain the antimicrobial agent fosfalin at their C-terminus. Three of the inhibitors also contain a 
second antimicrobial agent, β-chloroalanine, at the center of their tripeptide sequence. The identity 
of the N-terminal amino acid was varied in order to elicit selectivity via exploiting differences in 
permeability and hydrolysis rates within bacterial cells. 
We have shown that the β-chloro containing compounds elicit lower MIC values than their 
alanine analogues against a wide range of clinically relevant bacteria. This is consistent with release 
of free β-chloroalanine which then is able to act synergistically with the fosfalin unit. 
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Finally, we show that the MIC profiles of inhibitors 25a and 25c have potential for two differing 
real-world clinical applications. These are the detection of lung pathogens in cystic fibrosis patients, 
and the detection of Salmonella within stool samples for diagnosis of food poisoning, However, 
further work is required with large numbers of bacterial strains and relevant clinical samples to 
conclusively demonstrate the utility of these compounds. 
5. Patents 
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Abbreviations 
AcOH Acetic acid 
HCl Hydrochloric acid 
EtOH Ethanol 
CF3COOH Trifluoroacetic acid 
(CF3COO)2O Trifluoroacetic anhydride 
CH(OC2H5)3 Triethyl orthoformate 
NaBH4 Sodium borohydride 
tBoc N-tert-butoxycarbonyl protecting group 








r.t. Room temperature 
h Hour 
M Molarity 
PPEs Personal protective equipments 
OBzl Benzyl ester protecting group 
DIPEA N,N-Diisopropylethylamine 
IBCF Isobutyl chloroformate 
NMM N-methyl morpholine 
THF Tetrahydrofuran 
HBr Hydrogen bromide 
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